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Preliminary remark 
This dissertation is located in the interface area of oncology and sports science. 
To a large extent, this work is based on a randomized, controlled physical exercise 
intervention trial – the POSITIVE study Part III (from 2013 to 2017) with 232 
participants. The study has been approved by the ethics committee of the Medical 
Faculty Heidelberg, Germany. The author of this work was a doctoral student from 
the German Cancer Research Center and the Heidelberg University Hospital, 
Germany. She was significantly responsible for the coordination of the POSITIVE 
study Part III, including recruitments, collection of all clinically relevant data, 
anthropometric assessments, data management, execution and evaluation of 
physical performance tests, introduction of patients to the home-based exercise 
manual, and coordination and supervision of exercise sessions at the clinic during 
in-patient stay, overall from January 2014 to - last patient out - expected in 
December 2017. 
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1. Introduction 
Lung cancer accounts to the most commonly diagnosed cancer entities and 
represents the leading cause of cancer-related deaths worldwide. Patients with 
advanced lung cancer suffer of incurable disease with a limited prognosis and face 
a median survival of less than 12 months. In the course of disease and treatment, 
patients experience multidimensional impairments which may often result in 
physical fragility. Beneficial effects of physical exercise have been reported for 
early stage lung cancer patients. However, evidence demonstrating the efficacy of 
exercise interventions in patients with advanced disease remains unclear. The 
implementation of exercise interventions in patients with lung disease is often 
described as challenging due to physiological causes. As the lung is responsible 
for oxygen uptake, it is directly essential for physical capacity. Impairments of the 
lung itself display a performance-limiting factor. Thus, any reduction of oxygen 
absorption affects performance. This is an important fact to consider in studies 
addressing activities of daily living and physical exercise in patients with lung 
disease. 
In lung cancer patients, physical exercise interventions have been mostly 
implemented in the pre- and post-operative setting. Improvement has been 
observed for physical performance and cardiorespiratory fitness. For inoperable 
lung cancer patients, only few studies investigated the effects of physical exercise. 
The evidence in lung cancer patients with advanced disease derives from few 
single arm intervention trials with a small number of participants - mostly feasibility 
and observational studies. 
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This work represents the impact of a 24-week physical exercise intervention in 
patients with advanced lung cancer. Moreover, the focus of this work builds up on 
results, evaluations, and analyses of a specifically implemented physical exercise 
intervention trial in patients with advanced lung cancer - the POSITIVE study (Part 
III). 
In the following chapters, the background of lung cancer is presented and, 
therewith, the resulting relevant aspects for physical exercise therapy. Methods 
and design of the presented project are explained. The results and evaluations are 
presented and discussed afterwards. This work closes with a conclusion and 
summary. 
1.1 Background of lung cancer 
1.1.1 Epidemiology 
Lung cancer represents one of the most aggressive human cancers with a 5-year 
survival rate of 10-15% [43]. A five-year-overall survival rate of 2% is currently 
achieved in patients with metastatic disease [35]. Worldwide, lung cancer was the 
most commonly diagnosed cancer and the leading cause of cancer deaths among 
males in 2012 [48, 103] and it is the main cause for cancer-related deaths in 
Germany [10]. Overall, the highest incidence rates are reported for Northern 
America and Europe [104]. In men, lung cancer incidence rates were highest in 
Europe, Eastern Asia, and Northern America. In women, lung cancer was the 
second leading cause of cancer related deaths in less developed countries and 
the leading cause of cancer deaths in more developed countries. The incidence 
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rates were highest in Northern America, Northern and Western Europe, 
Australia/New Zealand, and Eastern Asia [103]. In Germany, approximately 
53,000 new diagnosed lung cancer cases are reported each year. The average 
age at diagnosis is 68.3 years in women and 69.3 years in men. While incidence 
rates for women are increasing, incidence rates in men are decreasing. 
Approximately 44,800 lung cancer deaths have been reported each year also 
indicating the trend in increasing numbers in women and decreasing numbers in 
men [10, 14]. 
1.1.2 Risk factors and carcinogenesis 
The pre-dominant cause for lung cancer is tobacco smoking including second-
hand smoke. Other causes include exposure to radon, occupational and/or 
environmental exposure to polycyclic circumstances  relevant to certain categories 
of work (asbestos, silica, e.g.), air pollution, specifically to particular matter and 
diesel engine exhaust, and indoor air pollution, including also second-hand 
tobacco smoke and emissions from household combustion of coal. Further risk 
factors describe alcohol use and cured meat consumption [10, 14, 38]. 
The genesis of malignant cancer cells is described as a multi-stage process which 
results in a complete malignant transformation. In lung cancer, two groups of 
cancer genes play an important role: the tumor suppressor genes and the cellular 
proto-oncogenes [60]. It is described that malignant cells proliferate in one (or 
both) lungs when previously normal cells change, increase, and multiply at an 
uncontrolled extent. Normal lung structure and function is disrupted by the 
resulting lesions. Once malignant cells spread to neighboring tissues and lymph 
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nodes, prognosis for the patient is poor [38]. Preventive screening for early 
detection for lung cancer is under development and has not yet been established. 
In most cases, the disease is discovered late. Poor survival of lung cancer patients 
is due, at least in part, to 80% of patients having distant metastases [43]. 
Advanced diseases are not eligible for surgery and had also been resistant to 
traditional chemotherapy. However, recent advances have led to exciting progress 
in therapies that are dependent on histology and genetics [14]. 
1.1.3 Clinical diagnostics 
For patients with signs and symptoms (see also 1.2 Symptoms and disease-
related impairment) of lung cancer, a chest X-ray is often the first evaluation 
examination. A computer tomography (CT) of the chest provides information on 
size and location of the tumor. According to the CT scan, determination of 
surgically resection is discussed. Besides CT, a positron emission tomography 
(PET) is additionally used for evaluating the mediastinum for lymph node 
metastases. In the evaluation of therapy response, CT scans are performed 
regularly [21]. 
For the determination of lung cancer pathology, a biopsy is required. The cell type 
is necessary to guide treatment. In addition of the determination of the cell type, 
specific evaluation for molecular characteristics (EGFR-, ALK-mutations, e.g.) are 
evaluated [65].  
Histologically, lung cancer is distinguished in Non-Small Cell Lung Cancer 
(NSCLC) and Small Cell Lung Cancer (SCLC) with a ratio of occurrence of 80% to 
20%. The histological types of NSCLC include adenocarcinoma, squamous cell 
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carcinoma and large cell carcinoma. Adenocarcinoma is the most common type 
and moreover often diagnosed in women without smoking history. Further 
subtyping on the base of molecular mutations is under development [14, 38]. 
1.1.4 Tumor classification and histology 
The criteria for the establishment of categories of the primary tumor (T1-T4) and 
status of lymph nodes (N1-N3) and metastases (M0, M1) are listed in the TNM-
atlas of the “Union international contre le cancer”. Besides the size of the tumor, 
infiltration of the pleura, distance of tumor expression to the hilar bronchus, and 
involvement of intrapulmonary lymph nodes are of interest. Thus, initial staging is 
performed according to the TNM-classification [72]. 
Lung cancer is classified in several stages (0, I, II, III, and IV), according to the 
size and location of the tumor, the number of invaded lymph nodes and tissue, and 
status of metastases [107]. In stage 0 to II, sometimes also in stage IIIA, a 
resection of the tumor is possible. In addition to surgery, radiation therapy (RT) 
and/or chemotherapy (CHT) are applied, in stages II and IIIA often as an adjuvant 
treatment [38]. If resection of the tumor is no option, patients are planned for 
palliative treatment including RT, CHT, a combination of RT and CHT (Radio-
chemotherapy, RCHT), or a targeted therapy. 
1.1.5 Treatment 
According to histology and stage, options of treatment include resection, 
radiotherapy (RT), chemotherapy (CHT), radio-chemotherapy (CHT), and/or 
targeted therapy. The number of planned cycles of CHT as well as the dimension 
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and scope of RT depends on the purpose of the therapy. Moreover, functional 
capacity of the patient (Karnofsky index, ECOG status) is crucial for therapy 
regimen. 
1.1.5.1 Non-Small Cell Lung Cancer (NSCLC) 
The consideration of treatment of NSCLC is decided in interdisciplinary exchange 
(tumor board). Treatment options include surgery, RT, and/or CHT. The overall 
goal of surgery is a post-operative absence of the tumor. With regard to the 
individual aim of the surgical intervention, it has to been distinguished between 
curative and palliative surgery. In early stage disease, a complete resection of lung 
and lymph nodes is often possible, often in combination with adjuvant RT. Further 
risk elimination is offered by adjuvant CHT within 60 days after surgery [27, 28, 
57]. The surgical intervention is often expanded by RT including curative, pre-
operative (neoadjuvant), post-operative (adjuvant), and palliative RT, and/or by 
CHT including simultaneously and sequentially applied RCHT [28]. In advanced 
disease, a complete resection is rarely an option. When a tumor resection is 
ineligible, RCHT is applied, depending on mobility and comorbidity status. In stage 
IV, the aim of treatment is to reduce symptoms while maintaining quality of life. 
Complementary and alternative options are targeted therapies with certain 
inhibitors (tyrosine kinase inhibitors, e.g.) [27, 28, 57]. 
1.1.5.2 Small Cell Lung Cancer (SCLC) 
SCLC is distinguished in limited disease and extensive disease. A major 
prognostic factor is considered in the extent of the disease and functional capacity 
of the patient. CHT - including mono- and poly-chemotherapy - is the backbone of 
treatment in SCLC. In limited disease stage, a surgery may sometimes be possible 
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in combination with adjuvant RT. Neo-adjuvant therapy is rarely common. In 
extensive disease stage, CHT is applied with cis- or carboplatin (depending on 
mobility and comorbidity status of the patient) in combination with etoposide [30]. 
The application of CHT of cisplatin and etoposide with contemporaneous RT is 
considered as the preferred therapy option [27, 28, 38, 57]. 
1.2 Symptoms and disease-related impairment 
Many patients are former or current smokers and often show up with symptoms 
related to smoking, such as chronic cough, a cough that gets progressively worse, 
chest pain, hemoptysis, shortness of breath, or multiple, repeated bronchial 
infections. Patients often may ignore these initial symptoms until they get more 
severe. Once a patient notices symptoms such as neurologic changes, bone 
and/or muscle pain, and jaundice, the cancer may have spread to distant organs 
[38]. Increased symptom levels (e.g. fatigue, dyspnoea, pain, appetite loss) and 
reduced quality of life in lung cancer patients compared to other cancer diagnoses 
like head and neck, gynaecological, prostate, breast, gastrointestinal, or bladder 
tumors have been reported in a Danish survey including n=1360 patients [50]. 
Furthermore, it has been shown that patients with advanced lung cancer have 
specific problems including - besides coughing and shortness of breath - anorexia 
and insomnia that also need to be addressed [22, 38, 47, 62]. 
The severity of the disease is described by “icon symptoms” as dyspnoea, fatigue 
and pain. Prominent symptoms also include depressions. Additional burden arises 
from socioeconomic problems, dealing with the change or loss of role function, 
facing physical fragility, and in many cases end of life decisions [100]. Moreover, 
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these patients face a very limited prognosis and have to deal with end-of-life 
decisions. Symptom load and existential distress is caused by anticancer 
treatment on the one hand and by the disease itself on the other hand. 
Psychological distress expressed by resignation, anxiety, and depression have 
often been described in these patients [9, 24, 46]. Within the last decade, an 
increasing focus on treatment-related side-effects regarding impairment in 
patients, in particular limitations and reduction of quality of life, pain, and cancer-
related fatigue, has been reported [42, 99]. Patients with metastatic or advanced 
NSCLC often experience multidimensional impairments affecting quality of life 
during their course of disease. Impairments and limitations result from 
comorbidities and symptoms of the disease. Side-effects and complications are 
caused by the anticancer treatment [50]. 
With regard to physical capacity, prominent described symptoms are reduced 
physical performance [100] and function [50] resulting in physical fragility. In recent 
years, physical aspects have increasingly gained importance. 
1.3 Physical activity and exercise in lung cancer patients 
In exercise oncology, research has been published for physical activity and 
exercise. According to the World Health Organisation (WHO), physical activity is 
defined as any bodily movement produced by skeletal muscles that requires 
energy expenditure. Regular moderate intensity physical activity – such as 
walking, cycling, or participating in sports – has significant benefits for health [110]. 
Whereas physical exercise is a planned, structured, and mostly repetitive 
intervention with a certain intention (conditioning any part of the body, improving in 
 Introduction 
  
Christina Titz  23 
strength and/or endurance, e.g.) [19]. In the context of this dissertation, both terms 
are used according to their certain definition. 
It has been reported that cancer patients are physically impaired both during and 
after [53] and also prior to anticancer treatment [70]. Physical exercise has been 
shown to alter symptoms in different tumor entities [89]. Based on evaluation on 
observational studies, an adequate level of physical activity has been 
recommended to reduce cancer-related symptoms and even cancer related death 
and all-cause mortality. Correspondingly, numerous studies have demonstrated 
that physical activity has a benefit on quality of life, physical capacity and fatigue in 
cancer patients, irrespective of the tumor type [59, 61, 69]. Specifically in lung 
cancer patients physical exercise studies showed an improvement in physical 
performance and cardiorespiratory fitness in the pre-and post-operative setting [5, 
41, 52, 54, 77]. 
Physical exercise is a commonly used measure to support medical treatment 
approaches in cancer patients. Various studies report that the implementation of 
physical exercise programs in cancer survivors is feasible and safe during and 
after cancer treatment [89] and about 100 studies provide data of biopsychosocial 
benefits related to exercise interventions [4, 36, 66, 86, 91, 92, 96]. There is broad 
evidence that aerobic as well as resistance training or a combination of both are 
beneficial for these patients [96]. Based on these findings a growing number of 
experts suggest that exercise programs should be integrated into standard care of 
patients undergoing cancer treatment [67]. To date recommendations mainly 
address early stage cancer patients, focusing on acute cancer treatments either 
pre- and/or post-surgery or afterwards in the rehabilitation/recovery period [89]. A 
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comprehensive review regarding the benefits of physical activity interventions in 
cancer patients with advanced disease has been done by Lowe et al. in 2011 [64]. 
Ten studies, including non-randomized trials, pilot trials, and feasibility studies, 
were included and analyzed relating to type of intervention, outcome parameter 
and assessment tools for symptoms, quality of life, physical performance and 
fatigue. The authors concluded that exercise as a supportive care intervention is 
promising. However, further studies are needed to substantiate preliminary 
findings and further advance this emerging area of research [102]. 
With regard on physical and functional aspects, anticancer treatment often induces 
muscle waste what is associated with reductions in quality of life. Loss of appetite, 
anorexia, insomnia, and vomiting are the main reasons for an insufficient nutrition 
uptake resulting also often in a loss of muscle mass. In lung cancer, muscle mass 
and associations to quality of life (QOL) have been evaluated. The results showed 
that maintaining muscle mass induces better QOL and physical functioning [15]. 
An increase in muscle mass – without showing sarcopenia at baseline – was a 
significant prognostic factor [95]. 
The relationship of physical performance and survival rates has been evaluated. In 
retrospective analyses, it has been shown that factors of physical performance 
(walking distance in 6MWT, e.g.) was a prognostic factor in lung cancer patients 
[53, 55] and metastatic breast cancer patients [51]. 
The importance of physical performance is considered with regard to treatment 
options. On the one hand, side-effects of both treatment and disease induce 
physical fragility and loss of physical performance. On the other hand, physical 
performance determines the therapy dose and extent, often even treatment 
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regimen (radio-chemotherapy vs. chemotherapy alone, e.g.). Thus, physical 
performance of cancer patients undergoing treatment gains increasingly 
importance. Moreover, physical performance also determines resection options 
when surgery is considered. 
For operable lung cancer patients, studies have been performed in the pre-
operative and post-operative setting [5, 41, 52, 77]. Improvement was 
demonstrated in physical performance and cardiorespiratory fitness. For lung 
cancer patients with advanced disease ineligible for surgery only few studies 
investigated the impact of physical exercise on quality of life [1, 82, 98]. The 
evidence in lung cancer patients derives from few single arm intervention trials 
with a small number of participants - mostly feasibility and observational studies. 
Temel et al. (2009) were the first to report beneficial effects of a structured 
exercise program in patients with advanced NSCLC. The eight-week program 
which had been conducted to patients shortly after diagnosis and was persecuted 
twice weekly led to a reduction in lung cancer symptoms and no deterioration in 6-
minute walk distance and muscle strength. They reported that less than half of the 
patients were able to complete the intervention. However, those who completed 
experienced an improvement in their lung cancer symptoms [98]. 
Improvements in physiological indices and emotional health-related quality of life 
have been reported for patients with advanced lung cancer undergoing palliative 
treatment [82]. The same group demonstrated beneficial effects of a 6-week 
hospital-based, structured, and group-based exercise program, patients with 
advanced lung cancer improved their physical and functional capacity, anxiety 
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level, and emotional well-being, however not in overall health-related quality-of-life 
[79]. 
Physical performance and psychosocial status in lung cancer patients have been 
evaluated in predominantly advanced disease stage (n=39; NSCLC stage IV: 73%; 
SCLC extensive disease: 64%; median age 62 years). Assessments for physical 
performance included muscle strength (maximum voluntary isometric contraction 
via handheld dynamometry) and endurance capacity (6-Minute walk distance). 
Psychosocial status was assessed by use of standardized questionnaires 
(Functional Assessment of Cancer Therapy – Lung, FACT-L). Performance status 
of the patients was compared to a healthy reference group. The results of this pilot 
trial indicated muscular weakness, lower endurance performance, and decreased 
quality of life in lung cancer patients [44]. This study (POSITIVE study, Part I) 
represents the first of three parts within the POSITIVE project. 
The subsequently conducted feasibility study (POSITIVE study, Part II) evaluated 
the effects of a combined resistance and endurance exercise intervention program 
in patients with advanced NSCLC. Within the intervention period of eight weeks, 
patients (n=40) were instructed to exercise at least 5x/week (inpatient setting) and 
at 3x/week (outpatient setting, homebased). Physical performance status 
(maximum voluntary isometric contraction of various muscle groups and 6-Minute 
walk distance), quality of life (FACT-L), fatigue (MFI), and depression (PHQ-9) 
were assessed at baseline, after the exercise intervention, and at a follow-up time 
point eight weeks later. The primary endpoint of the study was adequate 
adherence (feasibility) defined as completing training sessions at least 2x/week in 
at least six of eight weeks. Completers of the intervention showed a significant 
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improvement in 6-Minute walk distance and in knee-, elbow-, and hip muscle 
strength after the intervention period. Quality of life, fatigue, and depression scores 
remained stable or declined slightly. The authors concluded that exercise training 
is feasible in advanced and metastatic NSCLC patients during anticancer 
treatment. The improvement of endurance and strength capacity over time 
indicated the rehabilitative importance of the applied intervention [59]. 
The subsequent trial, the POSITIVE study (Part III), builds up on the pilot (Part I) 
and the feasibility study (Part II) and represents the base of the present work. 
1.4 Intention of this dissertation 
The studies mentioned above demonstrate that physical exercise beneficially 
affects not only psychosocial aspects in patients with cancer but also counteracts 
physical impairment in the course of disease and treatment related side effects. In 
lung cancer, supporting evidence exists for the pre- and post-operable setting 
while evidence of the effects of physical exercise in patients with advanced 
disease is lacking. 
This shall be shown in my thesis with the results of a systematic literature review 
on physical exercise in patients with advanced cancer. Moreover, the intention 
was to close the gap of lacking evidence with data from a randomized controlled 
physical exercise intervention trial - the POSITIVE study (Part III) 
(ClinicalTrials.gov NCT02055508). The objectives of the POSITIVE study (Part III), 
and therewith, the intention of this dissertation, was to close the gap of lacking 
evidence on physical exercise in patients with advanced lung cancer. To reach this 
goal, this dissertation covered the implementation of the POSITIVE study (Part III). 
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In the recently introduced POSITIVE study (Part I) and POSITIVE study (Part II), 
safety and feasibility represented the primary objectives. The subsequently 
conducted RCT should provide further evidence with behalf of the effects of the 
exercise training separately. Between November 2013 to December 2016, patients 
were recruited. In June 2017, the last patient has completed the intervention 
program and follow-up assessments are expected to be completed in December 
2017. 
The high quality of the study design helped to achieve a better reliability and 
validity for my dissertation. In advance of the POSITIVE study (Part III), a literature 
review was carried out to provide an overview on physical exercise in patients with 
advanced cancer. The publications that have been and will be published in the 
course of this dissertation address questions about the effects of a physical 
exercise program in lung cancer patients undergoing palliative treatment. 
An additional purpose of my thesis is to provide more knowledge for an optimal 
and efficient exercise therapy program as an integral part of cancer treatment for 
patients with non-operable lung cancer undergoing palliative treatment. 
1.4.1 Aims and objectives of this thesis  
The main objective of the studies presented in this thesis is to provide further 
insight into the impact of physical exercise in non-operable lung cancer patients 
during therapy on physical performance, to reveal potential benefits of a combined 
resistance and endurance exercise program during cancer treatment, and to 
evaluate how exercise prescriptions can be adapted and established for these 
patients. To reach this goal, the first publication provided a literature review of 
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physical exercise in advanced cancer patients. The second publication described 
the study design of the POSITIVE study (Part III) to introduce assessments, 
objectives, and analyses. The third publication evaluated physical exercise 
behavior in the year before and shortly after lung cancer diagnosis and analyzed 
physical performance status of patients compared to healthy reference data. The 
fourth publication (in preparation) will evaluate the effects of the 24-week physical 
exercise program of the POSITIVE study (Part III). Moreover, patients’ adherence 
and completion rates will be evaluated. The fifth publication (in preparation) will 
present results of the primary objectives of the POSITIVE study (Part III), which 
include analyses of the effects of a 12-week physical exercise on physical well-
being, quality of life, and physical fatigue in patients with advanced lung cancer 
and is not part of this thesis. The objectives of this dissertation included several 
aspects that will be presented in detail in the following. 
Notification: contents of the following sections are (partly) extracted from previous 
publications including Titz et al. 2016. Physical Exercise in Advanced Cancer 
Patients Undergoing Palliative Treatment. Expert Rev Qual Life Cancer Care 
[102], Wiskemann/Hummler, Diepold et al., 2016. POSITIVE Study: Physical 
Exercise Program in Non-Operable Lung Cancer Patients Undergoing Palliative 
Treatment. BMC Cancer. [109], and Titz et al. 2017. Physical Exercise Behavior 
and Performance Status in Patients with Advanced Lung Cancer. (under review) 
[101]. 
1.4.1.1 Physical Exercise in Advanced Cancer Patients Undergoing 
Palliative Treatment (1st publication) 
It has been described that with diagnosis and during treatment period patients, 
relatives and also health care professionals are faced with various challenges 
since patients often experience multidimensional impairments affecting quality of 
life [50]. Impairments derive from symptoms of the disease and/or comorbidities as 
well as from treatment-related side effects and additional burden arises from the 
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potential change or loss of role functions, facing physical fragility, and in many 
cases end of life decisions [100]. Physical exercise is a commonly used measure 
to support medical treatment approaches in cancer patients. Various studies report 
that the implementation of physical exercise programs in cancer survivors is 
feasible and safe during and after cancer treatment [89]. There is broad evidence 
that aerobic as well as resistance training or a combination of both are beneficial 
for these patients [96]. Based on these findings a growing number of experts 
suggest that exercise programs should be integrated into standard care of patients 
undergoing cancer treatment [67]. To date recommendations mainly address early 
stage cancer patients, focusing on acute cancer treatments either pre- and/or 
post-surgery or afterwards in the rehabilitation/recovery period [89]. The evidence 
on physical exercise in patients with advanced disease is unclear [102]. 
1.4.1.1.1 Objectives 
The aim of this review was to analyze the current evidence of randomized 
controlled physical exercise intervention trials in patients with advanced cancer. 
The selected studies were discussed with regard to the content of the exercise 
interventions, primary and secondary outcomes as well as physical performance 
testing procedures [102]. 
1.4.1.2 POSITIVE study: Physical Exercise Program in Non-Operable Lung 
Cancer Patients Undergoing Palliative Treatment (2nd publication) 
Numerous studies have shown that physical activity beneficially affects quality of 
life, physical capacity and fatigue in cancer patients, irrespective of the tumor type 
[59, 61, 69]. In lung cancer, exercise studies in the pre-and post-operative setting 
showed improvement in physical performance and cardiorespiratory fitness [5, 41, 
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52, 54, 77]. However, studies investigating the effects of physical exercise in non-
operable patients with advanced lung cancer are rare. Particularly, the number of 
randomized controlled trials is limited and current knowledge derives from 
feasibility and observational studies [1, 18, 79, 81, 98]. Physical exercise provides 
beneficial effects in cancer patients as shown by numerous investigations [20, 58, 
61]. Furthermore, there is strong evidence for physical exercise reducing cancer 
related fatigue [75] and there is some evidence from a limited number of studies 
that exercise has beneficial effects on quality of life in advanced lung cancer 
patients. Possible pathways how exercise may influence relevant lung cancer 
outcomes have not been studied yet. Therefore, the POSITIVE study (Part III) 
aims to investigate the benefits of a 24-week exercise intervention program in a 
randomized controlled setting. Beyond this, a translational program on 
immunological pathways will evaluate the potential relation between exercise-
driven immunological changes and the influence on tumor specific T cell response. 
In contrast to other published studies, the POSITIVE study (Part III) is designed to 
isolate the actual impact of a 24 week exercise intervention on quality of life by the 
unique characteristic that social support is provided to each study participant by 
weekly Care-Management-Phone-Calls (CMPC) [109]. 
1.4.1.2.1 Objectives 
The intention of the design paper of the POSITIVE study (Part III) was the 
introduction of the study design, eligibility criteria, assessments and analyses, and 
primary and secondary objectives. 
The primary endpoint was the impact of a 24-week combined endurance and 
resistance training plus CMPCs (interventional group) compared to CMPCs alone 
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(control group) on quality of life. Quality of life is measured by the FACT-L 
questionnaire, subcategory Physical Well-Being and General Fatigue measured by 
the Multidimensional Fatigue Inventory (MFI-20). Based on preliminary findings 
[44, 59], a beneficial effect on quality of life and fatigue scores for the 
interventional group compared to the control group after 12 weeks is expected. 
Furthermore, it is evaluated whether the intervention has a positive impact in terms 
of physical performance, depression, anxiety, demoralization and immunological 
parameters. In addition, sustainability and long-term effects of the intervention will 
be analyzed during the follow-up period [109]. 
1.4.1.3 Physical Exercise Behavior and Performance Status in Patients with 
Advanced Lung Cancer (3rd publication) 
Despite previous physical exercise intervention studies, knowledge of exercise 
behavior in patients with advanced lung cancer remains limited. These patients 
show decreased physical and emotional function and QOL when compared with 
other cancer diagnoses [50]. Physical fragility and limitations of functional capacity 
have been observed in advanced lung cancer patients [44, 100]. Increased QOL 
was associated with higher step counts as well as reductions in dyspnea, pain and 
depression scores [8]. Investigations concerning physical performance and self-
reported physical exercise behavior have not yet been reported in patients with 
advanced lung cancer. 
Therefore, physical performance and exercise behavior in patients with advanced 
lung cancer shortly after diagnosis based on baseline assessments of the 
POSITIVE study (Part III) were evaluated [101]. 
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The cross-sectional report including baseline data provided insight in exercise 
behavior of patients with advanced lung cancer. Physical activity, sports, and 
exercise in the year before and shortly after diagnosis (=at study enrolment) were 
evaluated and physical performance status of patients at study enrolment was 
compared with reference data. 
1.4.1.3.1 Objectives 
The objectives were to compare physical performance in these patients with 
reference data of healthy individuals and to evaluate the level of physical 
performance with regard to their previous (during childhood/adolescence; in the 
year before diagnosis) exercise and walking behavior and shortly after diagnosis 
[101].  
1.4.1.4 Effects of a 24-week Physical Exercise Program in Patients with 
Advanced Lung Cancer (in preparation) 
The aim of the intervention analysis was the evaluation of the 24-week exercise 
program of the POSITIVE study (Part III) with regard to physical performance 
parameters and analysis of patients’ adherence and completion rates. The primary 
goal was to evaluate the impact on endurance capacity and muscle strength 
performance. Change and progression of endurance and resistance performance 
have been evaluated and discussed. Furthermore, adherence to the exercise 
program and completion rates have been evaluated and discussed. Subgroup and 
explorative analysis provided insight in potential prognostic factors determining 
performance, adherence, and completion rates. The secondary aim was to 
address which patients have benefitted most of the physical exercise intervention 
program. 
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1.4.1.4.1 Objectives 
The analyses included different time periods of the intervention program which 
were considered and evaluated separately. The total intervention period of 24 
weeks was evaluated (Part 1). Additionally, the first (Part 2A) and second (Part 
2B) 12-week period of the physical exercise intervention program were evaluated. 
The subgroup and explorative analyses included primarily adherence 
characteristics (good vs. limited/inadequate) of the patients of the exercise arm, 
including evaluations on supervised and non-supervised/home-based exercise 
sessions. Clinical relevant characteristics with potential impact on physical 
performance were considered including lung cancer histology, treatment regimen 
at study enrolment, and patients’ exercise history. This is presented and discussed 
in the following work. 
  
 Methods and Design 
  
Christina Titz  35 
2. Methods and Design  
The following chapter is structured with regard to the methods and design of the 
within this thesis presented publications. These contain the literature review (2.1 
Physical Exercise in Advanced Cancer Patients Undergoing Palliative Treatment), 
the design paper of the POSITIVE study (Part III) (2.2 POSITIVE study: Physical 
Exercise Program in Non-operable Lung Cancer Patients Undergoing Palliative 
Treatment),  the cross-sectional baseline data analysis of the POSITIVE study 
(Part III) (2.3 Physical Exercise Behavior and Performance Status in Patients with 
Advanced Lung Cancer), and the intervention analysis of the POSITIVE study 
(Part III) (2.4 Effects of a 24-week Exercise Program in Patients with Advanced 
Lung Cancer). 
Notification: contents of the following sections are (partly) extracted from previous 
publications including Titz et al. 2016. Physical Exercise in Advanced Cancer 
Patients Undergoing Palliative Treatment. Expert Rev Qual Life Cancer Care 
[102], Wiskemann/Hummler, Diepold et al., 2016. POSITIVE Study: Physical 
Exercise Program in Non-Operable Lung Cancer Patients Undergoing Palliative 
Treatment. BMC Cancer. [109], and Titz et al. 2017. Physical Exercise Behavior 
and Performance Status in Patients with Advanced Lung Cancer. (under review) 
[101]. 
2.1 Physical Exercise in Advanced Cancer Patients Undergoing Palliative 
Treatment (Systematic literature review) 
2.1.1 Search strategy and selection criteria 
The analysis was based on a systematic literature search in the electronic online 
databases PubMed (MEDLINE), CINAHL, and the Cochrane Library. The 
databases were searched for randomized controlled exercise intervention trials in 
advanced cancer patients undergoing palliative treatment including the key words 
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palliative care, advanced cancer, and physical exercise. Only studies with no 
specific exercise treatment (“care as usual” or “treatment as usual”) applied in the 
control group were included. ‘Physical exercise’ in the intervention groups 
consisted of regular planned endurance or resistance exercise training or a 
combination of both. ‘Advanced cancer’ was defined as advanced disease in 
cancer patients with loco-regional or distant metastases (stage IV disease) not 
eligible for curative treatment including curative surgery. In the context of the 
review, ‘palliative treatment’ was defined as palliative oncologic treatment for 
advanced/metastatic disease with an estimated life expectancy of three months up 
to two years [37, 74] and a 5-year survival estimate of <50% [17]. 
2.1.2 Data extraction and validity assessment 
The preselected literature of the databases was read for titles regarding the 
defined inclusion criteria to make a first selection. This selection was read for 
abstracts whereby articles with matching titles found by hand search in the 
reference lists (snowball method) were also included. All selected abstracts were 
checked for relevance with regard to the purpose of this review. All articles not 
fulfilling the predefined inclusion criteria of the literature search were excluded, 
resulting in a final selection. Study contents were assessed in an overview table 
presenting entities, number of included patients, inclusion and exclusion criteria, 
questionnaires, primary and secondary endpoints, type of applied exercise, details 
of exercise intervention, duration of intervention, test procedures, and study results 
[102]. 
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2.1.3 Rating of study quality 
The study quality was assessed by using a checklist for randomized controlled 
trials provided by Schulz et al. [90]. The selected studies were rated based on the 
following criteria: (1) evidence of randomization, (2) statistical similarity of control 
and intervention group at baseline, (3) specification of eligibility criteria, (4) blinding 
of outcome assessors, (5) report of compliance, (6) supervision in exercise 
intervention program, (7) report of drop-outs, (8) presenting data for both primary 
and secondary outcomes, (9) intention to treat-analysis, (10) report of (severe) 
adverse events. Each criterion is worth 1.0 numerical point. Trials rated with seven 
points or higher are defined as high quality studies [102]. 
2.1.4 Statistical analyses 
The original literature only aggregated data of baseline and re-test (T1) 
assessment. In case of missing data, the responsible author was contacted. For 
descriptive presentation of change from baseline to re-test (T1), percentage 
differences based on the means of baseline and T1-assessments were computed. 
To enable comparisons across the different measure assessments, effect sizes 
(Hedge’s g) for the given outcome parameters were modified on recommendations 
by Morris and DeShon [71]. 
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2.2 POSITIVE Study: Physical Exercise Program in Non-operable Lung 
Cancer Patients Undergoing Palliative Treatment (Study design) 
2.2.1 Study design 
The POSITIVE study (Part III) was a randomized controlled intervention trial. All 
eligible patients who gave written informed consent were randomized (1:1) either 
to the control group or to the intervention group. The intervention was provided for 
24 weeks starting immediately after baseline assessment. Outcome measures 
were assessed at baseline (T0), after 12 weeks (T1), after 24 weeks (T2) and 
thereafter at 9 months (T3) and 12 months (T4), so that the maximum study 
duration per patient was one year (see Figure 1). The intervention group involved 
“Exercise Intervention Program (EIP) and Care Management Phone Calls 
(CMPC)” while the control arm performed “Care Management Phone Calls 
(CMPC)” only. The protocol of the POSITIVE study (Part III) has been reviewed 
and approved by the ethics committee of the Medical Faculty of Heidelberg (S-
326/2013). The POSITIVE study (Part III) was registered at ClinicalTrials.gov 
(registration number NCT02055508). 
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Figure 1: Design of the POSITIVE study (Part III) presenting the time points of endpoint and follow-
up assessments (T0 to T4). This figure has been adapted from the original figure of 
Wiskemann/Hummler, Diepold et al. (2016). 
2.2.2 Patients and setting 
Patients were screened by the study nurse for eligibility at the Clinic for Thoracic 
Diseases Heidelberg, Germany. Patients were informed when all inclusion criteria 
were present and exclusion criteria were absent. Inclusion criteria included 
histologically confirmed NSCLC stage IIIA, IIIB or IV or SCLC limited or extensive 
disease, non-eligible for surgery, date of first diagnose did not exceed three 
months (unless the patients were receiving first line EGFR+ or ALK+ tyrosine 
kinase inhibitors), planned or already receiving systematic treatment, age ≥18 
years, BMI ≥18 kg/m2, and mobility index ECOG ≤2. Main exclusion criteria were 
instable bone metastases, immobility, reduced condition, and symptomatic brain 
metastases treated with ≥8mg/day of Dexamethason [109]. 
2.2.3 Study interventions 
The intervention for all study patients of both study arms included weekly phone 
calls for symptom management and monitoring (care management phone calls; 
CMPCs). Patients in the exercise arm were additionally instructed to a home-
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based exercise program and were conveyed to a local (near patients’ home) 
training facility. The intervention period lasted for 24 weeks after baseline 
assessment. 
For patients with advanced lung cancer the adequate management of disease- 
and treatment-related side effects determine quality of life, psychosocial burden 
and the extent of fatigue. Therefore weekly phone calls were provided to all 
patients. The CMPCs were based on the Edmonton Symptom Assessment Scale 
(ESAS), a 9-item patient-rated symptom visual analogue scale developed for 
patients receiving palliative care. The modified version comprised of one additional 
question to assess the patient´s quality of life. Patients rated their symptoms on an 
11-point scale from 0 to 10 and at pre-specified cut off values (e.g. uncontrolled 
pain or breathlessness) the attending physician is contacted by the study nurse to 
manage symptoms and side-effects [109]. 
2.2.3.1 Exercise intervention program (EIP) 
The exercise intervention included supervised and non-supervised resistance and 
endurance exercise. During the first 12 weeks of the intervention program, 
supervised training sessions were conducted twice weekly with an additional self-
administered home based training once a week. With the beginning of week 13 
supervised training in cooperating training facilities was reduced to 1x/week and 
two home based training sessions per week were recommended. Training 
frequency was scheduled for three times a week. For endurance exercise, the 
training duration started at least 15 minutes minimum and ideally increase over 
time to 45 minutes depending on the patients’ individual capacity. Endurance 
exercise was carried out by a cycle ergometer, treadmill, or outdoor walking. The 
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intensity for endurance training was defined between 12 and 14 on the Borg Scale 
[13]. Training duration and intensity for resistance training sessions were adapted 
using the Borg Scale (14-16) and a well-established self-rating procedure from a 
lung cancer feasibility and allogeneic transplant study, also conducted of the 
Heidelberg group [108]. At the beginning of each training session patients are 
asked to self-assess pain, fatigue, emotional status, and distress. This self-
assessment was designed to help the patient choose the appropriate exercise 
volume category. There were three different categories, representing the traffic 
light colors red, yellow and green, for tailoring the exercise intervention. 
Depending on the color, patients set their individual training volume higher or 
lower. After each training session patients were asked to document their training in 
an exercise log. 
Inpatient exercise periods were conducted (supervised by the attending 
physiotherapist/sports scientist) at the exercise facilities of the clinic. Patients in 
the exercise intervention group were given a manual for individualized home 
based exercising. The program combined resistance (using body weights and 
rubber bands) and endurance (walking) instructions for brisk exercises. To allow 
for a supervised training near the patients´ home, patients performed exercise 
sessions in specific training facilities cooperating with the National Center for 
Tumor Diseases (NCT) Heidelberg. The supervised training sessions in the local 
training facilities comprised of resistance exercise on machines and endurance 
training on an ergometer/treadmill. Responsible exercise specialists in cooperating 
facilities were appropriately trained in the outpatient setting. 
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On the basis of the CMPCs the study nurse regularly reviewed exercise 
adherence and identifies barriers and problems with regard to exercise. Exercise 
sessions were stopped if pain, dizziness, or other contraindications (e.g. infections 
with body temperature ≥38°C, impaired hematopoietic capacity or 24 hours after 
receiving chemotherapeutical treatment with possible nephro- and/or 
cardiotoxicity) occurred. 
2.2.4 Physical function tests 
Data were collected at five time points (T0 – T4) every 12 weeks starting with 
baseline (T0). Accompanying the intervention period, testing procedures were 
carried out after 12 weeks and after weeks 24. After the intervention period, follow-
up testing procedures were executed 9 months and 12 months after baseline. 
Physical performance testing procedures included endurance and resistance 
testing procedures. Endurance testing included the walk distance of the 6-Minute 
walk test. Resistance testing was performed by maximum voluntary isometric 
contraction via handheld dynamometry of certain various muscles bilaterally. 
2.2.4.1 Endurance capacity 
The 6-Minute walk test (6MWT) [31] is a feasible and safe test to determine 
patients physical capacity and is well established in cancer patients [111]. The test 
was conducted on a ward floor at the clinic with 30 meters of distance. Patients 
were instructed to walk in six minutes as many meters as possible. Oxygen 
saturation and pulse rate were monitored before, during and after testing. After the 
test, patients were asked to rate their individual perceived exertion using the Borg 
Scale [13].  
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2.2.4.2 Muscle strength 
Maximum voluntary isometric contraction (MVIC) was measured according to 
defined and standardized test positions [11] via handheld dynamometry. The 
reliability of this test has been shown before in healthy individuals and patients. 
MVIC was assessed in knee extension, knee flexion (both in seated position with 
90° angle of knee flexion), elbow flexion, elbow extension, hip flexion, and hip 
abduction (all in recumbent position) for the dominant and non-dominant limb. 
Three attempts were performed in each muscle group and corresponding the best 
value (maximum value) was used for further calculations. Muscle strength values 
were recorded in Newton. Body weight adjusted muscle strength values were 
calculated in Newton per kilogram. Analyses include results of the dominant limb 
only. The dominant limb was defined at baseline. 
2.3 Physical Exercise Behavior and Performance Status in Patients with 
Advanced Lung Cancer (Cross-sectional baseline data analysis) 
2.3.1 Patient characteristics 
Medical characteristics were obtained from medical charts including histological 
diagnosis, stage of disease, and type of chemotherapy and/or radiotherapy. 
Patient demographics were self-reported and included marital status, educational 
background, employment status, and smoking history [101]. 
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2.3.2 Physical performance 
Physical performance assessments included the 6-Minute walk test (6MWT) and 
isometric strength testing (maximum voluntary isometric contraction, MVIC) of 
certain muscle groups of the upper and lower limbs via hand-held dynamometry 
(CITEC©, Netherlands). Only data of the dominant limbs are reported. Detailed 
information have already been presented in chapter “2.2.4 Physical function tests”. 
2.3.3 Exercise and walking behavior  
Exercise behavior was assessed with well-established self-reported patient 
questionnaires [78, 87] regarding sports/exercise at baseline, i.e. shortly after 
diagnosis, as well as retrospectively in the year before diagnosis and during 
childhood and adolescence (age <21 years). Information on walking behavior for 
walks of at least 20 minutes was collected additionally. 
For exercise and walking in the year before diagnosis and shortly after diagnosis, 
frequency (twice or more per week vs. once per week or less), duration (hours per 
week), and exercise type were assessed. For sports/exercise, intensity (light, 
moderate, intensive, or vigorous) was assessed additionally. The corresponding 
MET values were assigned using the tables of the Compendium of Physical 
Activities [2, 3]. MET*hours per week were calculated (categorized in >0-9 
MET*hours/week, >9-21 MET*hours/week, and >21 MET*hours/week) of the 
provided information on frequency, intensity and duration. The amount of minutes 
of physical exercise per week was calculated for moderate, intensive and vigorous 
activities to determine the percentage of patients meeting the current exercise 
recommendations of 150 minutes of moderate to vigorous physical activity (PA) 
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per week [85, 88]. Walking was considered as PA with no distinction being made 
between vigorous or moderate intensity. Walking and physical exercise were 
analyzed and considered separately [101]. 
2.3.4 Comparison of patient and reference data 
For comparison analyses, the predicted distance of the 6MWT was calculated for 
each patient via the validated formula of Enright et al. [32] according to sex, age, 
height, and weight. Reference data for MVIC was obtained from Bohannon et al. 
[11]. Reference data for muscle strength values of knee flexion have not been 
published and were not included in this analysis. 
2.3.5 Statistical analyses 
Patient demographics and medical characteristics were reported by descriptive 
analyses. Comparisons between observed and reference and standard data of the 
6MWT and MVIC were done by paired Student’s t-tests. Multiple regression 
analyses were performed to calculate determinants of physical performance in this 
patient population. Relative muscle strength values of elbow flexors and knee 
extensors and the distance of the 6MWT (in meter) of the baseline physical 
performance assessment were defined as independent variables. Demographic 
data (sex, age, body mass index (=BMI), smoking status), lung cancer histology, 
time between first diagnosis and study enrolment, status of metastases, as well as 
initial therapy regimen and information on previous and current (shortly after 
diagnosis) physical exercise behavior were considered as dependent variables. P-
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values below .05 were considered significant. All statistical calculations were 
performed with using SAS Enterprise Guide (version 6.1, SAS statistics) [101]. 
2.4 Effects of a 24-week Exercise Program in Patients with Advanced Lung 
Cancer (Intervention analysis including physical performance parameter) 
2.4.1 Intervention results  
Secondary endpoints of the POSITIVE study (Part III) were analyzed including 
physical performance (see “2.2.4 Physical function tests” for assessment of 
physical performance) and patients’ adherence and completion rates to the 
intervention program. Progression and change of physical performance parameter 
from T0 to T2 (24 weeks), from T0 (baseline) to T1 (12 weeks), and from T1 to T2 
(12 weeks) were evaluated. The intervention period of 24-weeks was divided in 
two periods of 12 weeks each. 
2.4.2 Patient adherence and completion rates 
Training adherence and completion rates were calculated according to the 
possible amount of exercise sessions within the intervention period. Patients in the 
exercise intervention program were asked to exercise (at least) 3 times per week. 
This required 36 training sessions within the first 12 weeks (week 0 – week 11) 
and another 36 training sessions within the second 12 weeks (week 12 – week 
24). Data on adherence and completion rate were calculated based on weekly 
records when conducting the patients. Separately, the exercise logs were 
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evaluated regarding type and intensity of exercise and duration. Frequency of 
exercise was covered in the weekly phone calls. 
The exercise intervention program included home-based and supervised exercise 
sessions 3x/week for 24 (2x12 weeks) weeks. Patient adherence was calculated 
by the amount of percent of completed sessions. Patients showed good 
adherence when exercising ≥3/week, and limited adherence when exercising 1-
2x/week. Inadequate adherence was reported for patients who did not exercise 
and/or were not able to exercise at all. Accordingly, the required weekly amount of 
exercise sessions was calculated and overall adherence was rated good, when 
>75% of the required exercise sessions were carried out, limited adherence when 
30-70% of the required exercise sessions were carried out and inadequate 
adherence when less than 30% of the required exercise sessions were carried out. 
The results and interpretation have to consider the reasons for poor adherence 
rates: loss of motivation or disease progression. Patients of the exercise arm were 
asked in the weekly phone calls (CMPC) about their effort in exercising. 
Additionally, the patients were asked to track their exercise sessions in an 
exercise log. 
The exercise log was implemented in the exercise manual and consisted of 24 
sheets - one sheet per week - and assessed information on exercise uptake 
according to the FITT criteria. The sheet showed a schedule from Monday to 
Sunday with the option for the patient mark with a cross what type of exercise 
(endurance, resistance, both), length of exercise sessions (<10 minutes, 10-20 
minutes, 20-30 minutes, >30 minutes), exercise alone (yes/no), and training facility 
(yes/no). Additionally, patients rated the intensity of their exercise session 
 Methods and Design 
  
Christina Titz  48 
according to the Borg scale (9-20). Patients were asked to exercise between 12 
and 14 for endurance exercise and between 14 and 16 for resistance exercise if 
there were no limitations or contraindications present. The patients were also 
asked to indicate if the exercise session was not carried out because it was not 
scheduled on that day or because of side-effects, lack of motivation or temporal 
aspects, e.g. 
2.4.3 Statistical analyses 
Clinical and patient demographics were calculated by descriptive analyses. 
Standard methods were used for data analysis. Data were analyzed on the intent-
to-treat-basis (ITT). Analysis of covariance (ANCOVA) was used with pre- to post-
intervention change as dependent variable, the intervention group (CMPC+EIP) as 
independent variable, and the baseline measure as covariate. All ANCOVAs were 
adjusted on sex and age. Randomization was stratified on histology 
(NSCLC/SCLC), treatment (thoracic-radiotherapy/no radiotherapy), brain 
metastases (yes/no), and sex (male/female). Besides ANCOVA calculations, 
individual percentage change from T0 to T1, from T1 to T2, and from T0 to T2 was 
calculated separately to better identify increase and decline in performance within 
different subgroups. 
In subgroup analyses, patient of the EIP-arm with good adherence (>75% of 
required exercise sessions) and patients with poor/inadequate adherence (<30% 
of required exercise sessions) were considered in directly comparison to the 
CMPC-arm. 
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Treatment-related analyses described the progression of performance of 6MWT 
and MVIC of elbow flexion and knee extension between the corresponding 
assessment points with regard to the applied treatment regimen. 
In explorative analyses, regression analyses were calculated to identify possible 
determinants for improvement in physical performance in patients with advanced 
lung cancer. Performance of 6MWT (meter), knee extension (Newton/kilogram), 
and elbow flexion (Newton/kilogram) at T1 and T2 were considered as dependent 
variables. Sex (male/female), age (≤62 years, >62 years), BMI (<20 kg/m2, 20-25 
kg/m2, ≥25 kg/m2), sports/exercise behavior before lung cancer diagnosis, days 
since study enrolment (<48 days, ≥48days), advanced/metastatic disease 
(yes/no), therapy (thoracic-radiotherapy alone, sequential chemo-radiotherapy, 
simultaneous chemo-radiotherapy, tyrosine kinase inhibitors, consolidating 
radiotherapy in SCLC patients, chemotherapy alone), adherence to the exercise 
intervention program (EIP-arm only; good, limited, inadequate) were considered as 
dependent variables. P-values below .05 were considered significant. All statistical 
calculations were performed with using SAS Enterprise Guide (version 6.1, SAS 
statistics). 
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3. Results 
In the following chapter the results of the publications presented within this thesis 
are demonstrated. This contains the results of the literature review (3.1 Physical 
Exercise in Advanced Cancer Patients Undergoing Palliative Treatment), the 
cross-sectional baseline data analysis of the POSITIVE study (Part III) (3.2 
Physical Exercise Behavior and Performance Status in Patients with Advanced 
Lung Cancer), and the intervention analysis of the POSITIVE study (Part III) (3.3 
Effects of a 24-week Exercise Program in Patients with Advanced Lung Cancer). 
Notification: contents of the following sections are (partly) extracted from previous 
publications including Titz et al. 2016. Physical Exercise in Advanced Cancer 
Patients Undergoing Palliative Treatment. Expert Rev Qual Life Cancer Care 
[102], Wiskemann/Hummler, Diepold et al., 2016. POSITIVE Study: Physical 
Exercise Program in Non-Operable Lung Cancer Patients Undergoing Palliative 
Treatment. BMC Cancer. [109], and Titz et al. 2017. Physical Exercise Behavior 
and Performance Status in Patients with Advanced Lung Cancer. (under review) 
[101]. 
3.1 Physical Exercise in Advanced Cancer Patients Undergoing Palliative 
Treatment 
The literature search resulted in 960 studies of which six trials met the eligible 
criteria and were selected for the review. Altogether, the selected trials enrolled 
590 patients with three studies including various tumor entities [17, 74, 83], two 
studies including breast cancer [37, 63], and one study including prostate cancer 
patients [33]. The analyzed studies included 243 men and 347 women. The most 
common cancer types were breast (n=205), gastrointestinal (n=112), lung (n=73), 
and prostate cancer (n=71). All patients showed advanced disease. The average 
age of patients across the reported studies was 59.3 years. 
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For physical performance assessment, the Tinetti gait and balance test and 30-
meter walk test [17], one repetition maximum testing (chest press, seated row, leg 
extension, leg press), timed chair rise to standing (5 times), 6-meter usual and fast 
walk, and a 400-meter walk [33], the chair-stand test [83], Bruce Ramp treadmill 
test [63], and sit-to-stand, grip strength, maximal step length, and shuttle walk test 
[74] were used for physical performance testing procedures (see Table 1). 
The primary endpoints of the selected studies included physical well-being and 
fatigue [17], body and regional lean mass [33], fatigue and quality of life [37], 
physical fatigue [74], and chair-stand test [83]. Secondary endpoints included 
muscle strength and function, cardiorespiratory capacity, blood biomarkers and 
quality of life [33], physical performance [74], and pain score [83], and physical 
functioning [63] (see Table 1). 
The exercise types included combined progressive resistance and aerobic 
exercise [33], structured physical therapy [17], resistance training [83], supervised 
circuit training [74], moderate-intensity aerobic exercise program [63], and home 
videotape, seated exercise program [37]. The duration of the intervention 
programs lasted between eight and 14 weeks [33, 63, 74, 83]. In two studies, the 
duration was not defined on a certain amount of weeks but on the amount of 
sessions (eight sessions) [17] or cycles of chemotherapy (four cycles) [37]. 
For physical performance, significant results were shown for the shuttle walk test 
after an eight-session truncal and upper-limb strengthening program [74] and for 
the timed chair-stand test after a 2-week inpatient plus a 12-week home-based 
isometric resistance training program [83]. Significant changes in muscle strength 
for chest press, seated row, leg press, and leg extension after a 12-week machine-
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based resistance training were observed [33]. With regard to the 400-m walk, chair 
rise to standing and stair climbs assessment, the effect sizes are negative since a 
reduction in time (all in seconds) corresponds to a better performance. For 
parameters regarding the numbers of repetitions, centimeter or meter, the effect 
sizes are positive. The relative improvement (% change) indicates the extension of 
change between baseline and retest assessment. In the remaining studies, 
physical performance was not tested/not assessed [37] or studies provided only 
baseline results for physical performance [17], or just reported change without 
providing pre- and post-testing values [63]. 
For quality of life, the Spitzer Uniscale, the Linear Analog Self Assessment of 
physical well-being [17], the Short Form-36 (SF-36) [33], and the Functional 
Assessment of Chronic Illness Therapy-Fatigue Version IV (FACIT-F) [37] were 
used. Studies found improved physical well-being scores [17] and also greater 
changes in general health (p=.022), vitality (p=.019), and the physical health 
composite scores (p=.020) in the exercise group [33]. In a mixed modeling 
approach, a decline in QOL scores for the entire patient cohort was observed with 
the application of a third cycle of chemotherapy [37]. However, the decline in the 
exercise group was significantly slower (p=.02) compared to the control arm. For 
physical functioning and overall QOL (EORTC-QLQ-C30), no significant increases 
were reported for the intervention group [63]. 
Further analyzed outcomes included fatigue and pain. Three studies included 
fatigue scores as a primary endpoint [17, 37, 74]. Overall, no significant effects 
were reported. A trend was observed in favor of the exercising groups. Beneficial 
effects for fatigue were also described in the 12-week resistance training trial in 
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prostate cancer patients, where fatigue scores had been significantly reduced in 
the exercise group [33]. However, these findings were inconsistent to Oldervoll et 
al. and Cheville et al. [17, 74]. For pain, Rief et al. demonstrated reduced pain 
perception in advanced cancer patients exercising during and after palliative 
radiotherapy for vertebral bone metastasis in comparison to non-exercising 
controls [83]. 
The reported adherence rate (training frequency) was between 69% and 94% and 
there were no differences observed between supervised (69-78%) and non-
supervised (75%) exercise interventions. One study reported higher study attrition 
in the exercise group than in the control group (14 participants vs. 8 participants, 
p=.15) [63]. No adverse events either during testing procedures or exercise 
sessions were reported [33, 63, 74]. 
 
Table 1: Results of the literature review including entities, number and gender of enrolled patients, primary and secondary endpoints, exercise intervention 
contents and test procedures, as well as a summary of the results of the presented studies themselves. This table has been adapted from the original tables 
of Titz et al., 2016. 
Study Entity N (m/f) 
Primary 
endpoints 
Secondary 
endpoints 
Exercise intervention Test procedures Results 
        
Cheville et 
al., 2010 
[17] 
mixed
A 
66:37 Physical 
well-being, 
fatigue 
 
- Truncal and upper-limb strengthening 
activities alternated between standing and 
seated exercise; educational components. 
Tinetti gait and balance test, 
30-meter walk test  
Intervention group improved mean physical 
well-being scores  
        
Galvão et 
al., 2010 
[33] 
prostate 57:0 Body and 
regional lean 
mass 
Muscle 
strength and 
function, 
cardiorespirat
ory capacity, 
blood 
biomarkers, 
quality of life. 
Resistance exercise: Chest press, seated 
row, shoulder press, triceps extension, leg 
press, leg extension, leg curl, abdominal 
crunches. 
12- to 6-RM for 2-4 sets; aerobic exercise: 
15-20 min of cycling/walking/jogging, 65%-
80% of HRmax (Borg Scale 6-20). 
Small groups of 1-5 participants. 
DXA (whole body and 
regional lean mass, fat 
mass, percent fat) 
1-RM (chest press, seated 
row, leg extension, leg 
press); chair rise to standing 
(5 times); 6-m usual and fast 
walk, cardiovascular 
capacity 400-m walk 
Patients of the exercise group showed an 
increase in lean mass (total body, P=.047; 
upper limb, P>.001; lower limb, P=.019) and 
better muscle strength (P<.01); 6-m walk 
time (P=.024) and 6-m backward walk time 
(P=.039). 
Patients of the exercise group showed 
improved QOL including general health 
(P=.022) and reduced fatigue (P=.021). 
        
Headley et 
al., 2004 
[37] 
breast 0:38 Exercise, 
fatigue, 
Quality of 
life 
- Homebased via video “Armchair Fitness: 
Gentle-Exercise”, 3 times a week (at least a 
one-day break between sessions), 5 minute 
warm-up, 20 minutes of moderate-intensity 
repetitive motion exercises, 5 minute 
cooldown. 
 FACIT-F-scores declined but at a slower rate 
for the experimental group (p=0.02). Fatigue 
scores indicated less increase and physical 
well-being subscale scores showed less 
decline for the experimental group (P=0.008 
and P=0.02).  
        
Oldervoll et 
al., 2011 
[74] 
mixed
B 
87:144 Physical 
fatigue 
Physical 
performance 
Circuit Training consisting of lower and 
upper limb muscle strength, standing 
balance, and aerobic endurance 
Sit-to-stand, grip strength, 
maximal step length, shuttle 
walk test. 
Intervention group improved in shuttle walk 
test (P=.008) and grip strength test (P=.01) 
        
Rief et al., 
2014 [83] 
mixed
C 
33:27 Chair-stand 
test 
Pain score Three different exercises to ensure an even 
isometric training of the muscles along the 
entire vertebral column. 
Chair-stand test In the intervention group, fatigue and 
psychological stress decreased (p<.001), 
patients improved in the chair-stand tests 
(p<.0001), intervention group improved in 
pain scores (p<.001)  
        
Ligibel et al., 
2016 [63] 
breast 0:101 Physical 
functioning 
Physical 
performance, 
Quality of life, 
Fatigue 
Weekly in-person meetings within the first 
month and monthly thereafter, weekly 
telephone contacts. Goal: 150 minutes of 
moderate-intensity exercise /week. 
Participants were provided with a heart rate 
monitor, pedometer, and an exercise journal. 
Participants were provided with a 16-week 
membership to a local gym. 
Bruce Ramp treadmill test The intervention group experienced a non-
significant increase with regard to minutes of 
weekly exercise (p=0.17), physical 
functioning (p=0.23), and Bruce Ramp 
treadmill test (p=0.35). Study attrition was 
higher in the exercise group than in the 
control group. 
A
 Gastrointestinal (n=39), Head and neck (n=18), Lung (n=15), Brain (n=12), Sarcoma (n=3), endometrial (n=2), breast (n=4), mesothelioma (n=1), lymphoma 
(n=2), cervical (n=1), melanoma (n=1), vaginal/vulvar (n=3), Merkel cell (n=1), metastatic carcinoma of unknown primary (n=1); 
B
 Gastrointestinal (n=73), 
Breast (n=51), Lung (n=38), Urological (n=30), Gynecological (n=12), Haematological (n=7), Other (n=20); 
C 
Lung (n=20), Breast (n=11), Prostate (n=14), 
Melanoma (n=2), Renal (n=3), Other (n=10). 
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3.2 Physical Exercise Behavior and Performance Status in Patients with 
Advanced Lung Cancer 
Within the POSITIVE study (Part III), 2557 patients were screened for eligibility 
between November 2013 and December 2016 (see Figure 2). Due to at least one 
present exclusion criterion 1954 patients (76.4%) were excluded. In total, 301 
patients (11.8%) declined participation and 70 patients (2.7%) were not enrolled 
due to organizational flow (n=63) or death of the patient prior to the first contact 
with the study personnel (n=7). 232 patients (9.1%) were enrolled in the study (132 
men, 98 women, mean age 62.2±8.8, range 26-79 years). 151 patients (66.5%) 
showed metastatic disease at study enrolment. Approximately 88% of the patients 
were current (43.2%) or ex-smokers (44.5%). Twenty-eight patients (12.3%) were 
never smokers [101]. 
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Figure 2: Recruitment flow-chart of the POSITIVE study (Part III) with the total number of overall 
screened lung cancer patients and excluded patients, patients being not enrolled, patients being 
contacted, patients who rejected a participation in the study, and patients who gave written 
informed consent. 
3.2.1 Exercise and walking behavior 
The baseline patient questionnaire assessing sports/exercise and walking 
behavior was completed by 213 patients. In childhood and adolescence (age ≤21 
years) 139 (61.2%) patients participated in any sports beyond physical education 
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at school with 53 patients reporting competitive sports. The average duration of 
participation was 4.0±0.45 years. In the year before diagnosis, ninety-seven 
(42.7%) patients reported regular participation in sports/exercise and 79 patients 
(34.8%) exercised more than twice a week. Fifty-three patients (23.3%) showed 
>21 MET*hours per week. Patients performed endurance training (18.5%), 
resistance training (12.8%), or other sports/exercise (11.5%). 116 patients (51.5%) 
did not participate in regular sports/exercise. The recommended 150 minutes of 
moderate PA per week according to the ACSM guidelines were met by 64 patients 
(28.2%). Shortly after diagnosis - at study enrolment - 46 patients (20.3%) 
reported participation in sports/exercise. 167 patients (73.6%) reported no regular 
participation in physical exercise. Of those who reported PA, 34 patients (15.0%) 
met the ACSM guidelines. With regards to the FITT criteria, a decrease of at least 
50% in frequency (-57%, 79 vs. 34), duration (-50%, 64 vs. 32) and intensity (-
54%, 90 vs. 41) was observed from in the year before to shortly after diagnosis 
[101]. 
3.2.2 Physical performance 
3.2.2.1 Muscle strength 
MVIC was assessed in 209 patients. Muscle strength values of the lung cancer 
population and their corresponding reference values [11] are presented in Table 2 
for men and women. In men, significant differences were for hip abduction (p<.01) 
and knee extension (p<.01). In women, significant differences were observed in 
elbow flexion (p<.01) in favor of the patients. Strength values in knee extension 
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and hip abduction were significantly lower (p<.01) compared to the reference data 
[101]. 
3.2.2.2 Endurance capacity 
Baseline assessment for 6MWT was completed by 211 patients. Both men and 
women showed significantly lower performance (p<.01) compared to the 
calculated normative data [101]. The results are presented in Table 2. 
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Table 2: Deviations of strength performance of elbow flexion, elbow extension, hip flexion hip 
abduction, and knee extension and endurance capacity (6-minute walk distance in meter) from 
reference and standard data at baseline in male and female patients. This table has been adapted 
from the original table of Titz et al., 2017. 
 
 
Men 
  Strength performance (N/kg) 
 n mean SD Ref
A 
p-value 
Elbow flexion 117 3.12 0.67 3.23  
Elbow extension 116 2.17 0.53 2.17  
Hip flexion 110 2.27 0.59 2.18  
Hip abduction 120 2.33 0.48 3.36 ** 
Knee extension 121 4.59 1.05 5.06 ** 
      
  Endurance performance (m) 
 n mean SD Ref
B 
p-value 
Walk distance 120 478.3 93.5 580.9 ** 
      
      
      
Women 
  Strength performance (N/kg) 
 n mean SD Ref
A 
p-value 
Elbow flexion 81 2.50 0.55 2.25 ** 
Elbow extension 82 1.65 0.41 1.58  
Hip flexion 83 1.87 0.62 1.74  
Hip abduction 84 2.10 0.50 2.90 ** 
Knee extension 88 4.12 1.07 4.57 ** 
      
  Endurance performance (m) 
 n mean SD Ref
B 
p-value 
Walk distance 91 441.5 104.2 506.8 ** 
      
Abbreviations: SD=standard deviation; N/Kg= Newton/kilogram; m=meter
 
A
mean of reference data of Bohannon et al. 1997 in N/kg; 
B
mean of calculated standard data 
according to the formula of Enright et al. 2003 in m; *p<.05; **p<.01. 
 
3.2.3 Determinants of physical performance 
Male sex was significantly associated with higher physical performance in walk 
distance (p<.05), elbow flexion (p<.0001), and knee extension (p<.01). Lower age 
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was significantly associated with higher physical performance in walk distance 
(p<.0001), elbow flexion (p<.05), and knee extension (p<.01). For patients with 
BMI ≥25 kg/m², significantly lower performance in elbow flexion (p<.01) and knee 
extension (p<.01) compared to patients with lower BMI were observed. In elbow 
flexion, patients with median date of first diagnosis <48 days performed 
significantly better (p<.01). Metastatic patients showed significantly higher 
performance in the 6MWT (p<.05). With regard to exercise behavior, significant 
associations were observed between sports/exercise during 
childhood/adolescence and knee extension (p<.05). Patients who participated in 
walking in the year before diagnosis performed significantly better during the 
6MWT (p<.01) at baseline [101]. The results for walk distance and knee extension 
are presented in Table 3. 
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Table 3: Results of multiple regression analysis of strength performance (knee extension) and 
endurance capacity (6-minute walk distance) in correlation to sex, age, body mass index, smoking 
status, lung cancer histology, upfront radio-chemotherapy, days between enrolment and date of 
first diagnosis, metastatic status, sports/exercise history (adapted from the original table of Titz et 
al., 2017). 
    
Variables  Walk distance (m) Knee extension (N/kg) 
  R
2
: .23 R
2
: .21 
 
 
Beta
A 
p-value Beta
A 
p-value 
      
Sex female -35.46 * -0.48 ** 
male reference    
  
Age <62 years 54.51 *** 0.46 ** 
≥62 years reference    
  
Body mass index <20 kg/m
2 
-10.23 
 
0.70 ** 
20-25 kg/m
2 
0.03 
 
0.64 *** 
≥25 kg/m
2 
reference    
  
Smoking yes -10.75 
 
-0.01  
no reference    
  
Lung cancer histology NSCLC 11.75  -0.15  
SCLC reference    
  
Upfront radio-chemotherapy yes 32.35  -0.09  
 no reference    
  
Days between enrolment and 
date of first diagnosis 
(median) 
≥48 days
B 
-0.62  -0.19  
<48 days reference    
 
  
Metastasis yes 31.91 * 0.05  
 no reference    
      
Sports/exercise in 
youth/adolescence
C 
yes 26.12 
 
0.34 * 
no reference    
 
Sports/exercise in the year 
before diagnosis
C 
yes 27.33  0.18  
no reference    
 
Walking in the year before 
diagnosis
C 
yes 57.36 ** 0.31  
no reference    
      
A
Regression coefficient from multiple regression model, all variables were included simultaneously 
in the model; 
B
48 days=median of time between date of first diagnosis and study enrolment; 
C
based on the self-reported patient-questionnaire; *p<.05; **p<.01; ***p<.0001. 
  
 Results 
  
Christina Titz  62 
3.3 Effects of a 24-week Physical Exercise Intervention in Patients with 
Advanced Lung Cancer  
Between November 2013 and December 2016, 232 patients were enrolled in the 
POSITIVE study (Part III) and four patients had to be excluded from analysis due 
to eligibility for surgery after two cycles of chemotherapy. The evaluation of the 
intervention included 223 patients (128 men, 95 women, mean age 62.2±8.9, 
range 26-79 years). 112 patients were allocated to the EIP+CMPC-arm (=EIP), 
111 patients to the CMPC-arm. More than half of the patients (57.0%) presented 
ECOG 0 at study enrolment. Thirty patients (13.5%) were never smokers, 130 
patients (58.3%) were former smokers and 62 patients (28.3%) were current 
smokers. The level of education was rather low in 134 patients (64.7%). More than 
two thirds of the patients (66.8%) presented metastatic disease at the time of 
study enrolment and 78.4% were diagnosed with NSCLC, 21.6% with SCLC. 
Thirty-five patients (15.7%) showed brain metastasis at study enrolment. More 
than two thirds of the patients (71.3%) received chemotherapy alone. Twenty 
patients (9.0%) were undergoing sequential chemo-radiotherapy and 23 patients 
(10.3%) simultaneous chemo-radiotherapy. Ten patients (4.5%) received 
radiotherapy alone and another ten patients (4.5%) were treated with tyrosine 
kinase inhibitors (TKI). One patient (0.5%) received immunotherapy at study 
enrolment. With regard to physical exercise behavior in this patient population, 109 
patients (53.4%) reported sports/exercise before diagnosis while 95 patients 
(46.6%) patients reported no participation in any sports/exercise. The baseline 
patient characteristics showed no significant differences between the EIP- and 
CMPC-arm. Patient characteristics are shown in Table 4. 
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Table 4: Patient characteristics at study enrolment/baseline of the POSITIVE study (Part III) 
presented in total (n=223) and separated by study arm (EIP, n=112; CMPC, n=111) including sex, 
age, body mass index, weight and height, weight loss since initial diagnosis, performance status 
(ECOG), smoking status, education status, lung cancer histology and stage, metastatic status, 
therapy regimen, sports/exercise history. 
 
TOTAL EIP CMPC 
        
Total, n (%)  223 (100) 112 (100) 111 (100) 
        
Sex, n (%) Male 128 (57.4) 63 (56.2) 65 (58.6) 
 Female 95 (42.6) 49 (43.8) 46 (41.4) 
        
Age, mean (SD)  62.2 (8.9) 62.6 (9.1) 61.8 (8.9) 
BMI
A
 (kg/m
2
), mean (SD)  25.3 (4.5) 25.1 (4.6) 25.3 (4.4) 
Weight (kg), mean (SD) 75.6 (15.8) 74.4 (15.9) 76.9 (15.6) 
Height (cm), mean (SD) 172.7 (0.1) 171.6 (8.7) 173.9 (9.4) 
Weight loss since diagnosis (kg), mean (SD) 2.5 (3.7) 2.2 (3.8) 2.8 (3.7) 
        
ECOG
B
, n (%) 0 127 (57.0) 65 (58.0) 62 (55.9) 
 1 91 (40.8) 46 (41.1) 45 (40.5) 
 2 5 (2.2) 1 (0.9) 4 (3.6) 
        
Smoking status, n (%) Never smoker 30 (13.5) 12 (10.7) 18 (16.2) 
 Current smoker 63 (28.3) 35 (31.3) 28 (25.2) 
 Former smoker 130 (58.3) 65 (58.0) 65 (58.6) 
        
Education status, n (%) Low 59 (28.5) 31 (29.3) 28 (27.7) 
 Basic 75 (36.2) 42 (39.6) 33 (32.7) 
 Advanced 39 (18.8) 17 (16.0) 22 (21.8) 
 Academic 33 (15.9) 16 (15.1) 17 (16.8) 
 None 1 (0.5)   1 (1.0) 
 Missing 16  6  10  
 
Lung cancer histology and 
stage, n (%) 
NSCLC
C
 IIIA 9 (4.0) 5 (4.5) 4 (3.6) 
NSCLC IIIB 48 (21.5) 19 (17.0) 29 (26.1) 
 NSCLC IV 118 (52.9) 63 (56.3) 55 (49.6) 
 SCLC
D
 LD 17 (7.6) 10 (8.9) 7 (14.4) 
 SCLC ED 31 (13.9) 15 (13.4) 16 (6.3) 
        
Metastasis, n (%) None 74 (33.2) 34 (30.4) 40 (36.0) 
 Brain 35 (15.7) 20 (17.9) 15 (13.5) 
 Other 114 (51.1) 58 (51.8) 56 (50.5) 
        
Therapy, n (%) Chemotherapy alone 159 (71.3) 79 (70.5) 80 (72.1) 
 Radio-chemotherapy (sequ
E
) 20 (9.0) 11 (9.8) 9 (8.1) 
 Radio-chemotherapy (sim
F
) 23 (10.3) 12 (10.7) 11 (9.9) 
 Radiotherapy alone 10 (4.5) 5 (4.5) 5 (4.5) 
 Tyrosine kinase inhibitors 10 (4.5) 4 (3.6) 6 (5.4) 
 Immunotherapy 1 (0.5) 1 (0.9)   
 
Sports/exercise before 
diagnosis, n (%) 
Yes 109 (53.4) 59 (56.7) 50 (50.0) 
No 95 (46.6) 45 (43.3) 50 (50.0) 
Missing 19  8  11  
        
A
BMI: Body mass index; 
B
ECOG: Eastern Co-Operative Oncology Group, standardized mobility index; 
C
Non-Small Cell Lung Cancer; 
D
Small Cell Lung Cancer; 
E
sequentially performed radio-chemotherapy; 
F
simultaneously performed radio-chemotherapy. 
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There were six non-starters in the CMPC-arm and one non-starter in the EIP-arm. 
Within the first 12 weeks of the intervention - from T0 to T1 - there were five drop-
outs in the CMPC-arm (withdrawal of informed consent n=3; unable to perform 
intervention n=2) and six drop-outs in the EIP-arm (withdrawal of informed consent 
n=4; unable to perform intervention n=2). In the CMPC-arm, three patients died 
before T1 and three patients were lost-to-follow-up. In the EIP-arm, five patients 
died before T1 and two patients were lost-to-follow-up. 149 patients (66.8%) have 
completed T0 and T1 assessment and change and progression of physical 
performance was analyzed. 
Within the second 12 weeks of the intervention - from T1 to T2 - there were two 
drop-outs in the CMPC-arm (unable to perform intervention n=2) and four drop-
outs in the EIP-arm (withdrawal of informed consent n=4). In the CMPC-arm, eight 
patients died from T1 to T2 and six patients were lost-to-follow-up. In the EIP arm, 
three patients died from T1 to T2 and six patients were lost-to-follow-up. 89 
patients (39.9%) have completed T1 and T2 assessment and change and 
progression of physical performance was analyzed. 
Overall, including the entire intervention period of 24 weeks from T0 to T2, there 
were seven drop-outs in the CMPC-arm and eleven patients died and another 
seven patients were lost to follow up. In the EIP-arm, there were ten drop outs in 
total, eight patients died and eleven patients were lost to follow up. Ninety-five 
patients (42.6%) have completed T0 and T2 assessment and change and 
progression of physical performance was analyzed (see Figure 3). 
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Figure 3: CONSORT diagram of assessed physical performance parameter of the POSITIVE 
study (Part III) from T0 to T2. 
 
The presented results of the POSITIVE study (Part III) covered the entire 
intervention period and include assessment of physical performance (6MWT and 
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MVCI) at baseline (T0), 12 weeks after baseline (T1) and 24 weeks after baseline 
(T2). To generate analyses separately not only for the entire intervention period 
but also for the first and second 12 weeks of the intervention, the presentation of 
the results was split up as follows: 
 Change and progression of endurance and strength capacity throughout the 
entire intervention period (T0 to T2) are presented in Part 1 (3.3.1 Part 1: 
Intervention results from T0 to T2 (24 weeks)) including analyses of 
patients’ adherence to the exercise program and explorative analyses. 
 Change and progression of physical performance parameter are separately 
presented in Part 2 for the period from T0 to T1 (Part 2A) (3.3.2 Part 2A: 
Intervention results from T0 to T1) and from T1 to T2 (Part 2B) (3.3.3 Part 
2B: Intervention results from T1 to T2) including also analyses of patients’ 
adherence to the exercise program and explorative analyses. 
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3.3.1 Part 1: Intervention results from T0 to T2 (24 weeks) 
3.3.1.1 Patient adherence (T0-T2) 
The analyses of adherence to the intervention program from T0 (week 0) to T2 
(week 24) were based on 112 patients of the EIP-arm. One patient withdrew from 
participation before baseline assessment and eight patients did not start the 
exercise intervention due to being overwhelmed and/or exhausted (n=4) and 
treatment-related side-effects (n=4). From T0 to T2, seven patients (6.3%) 
dropped out, eleven patients died (9.8%), and seven patients (6.3%) were lost-to-
follow up. 
3.3.1.1.1 Adherence according to weekly patient-reported information 
via CMPC 
Adherence to exercise program was evaluated for 108 patients (96.4%). Patients 
reported a mean of 41.0±23.9 of 72 required exercise sessions, 6.7±6.7 in training 
facilities. Thirty patients (26.8%) reported ≥75% of required exercise sessions and 
exercised regularly supervised in a training facility (see Table 5). 
3.3.1.1.2 Adherence according to exercise log 
Exercise logs of 72 patients (64.3%) were analysed. In total, 4437 exercise 
sessions were reported from T0 to T2, of which at least 776 exercise sessions 
were performed in a training facility and 2249 exercise sessions were performed 
home-based. On average, patients exercised at level 13 (range 5-19) on the Borg 
Scale. Patients performed 1028 exercise sessions <20 minutes, 2407 sessions 
>20 minutes. Patients rather exercised alone compared to group-based exercise 
or with a partner (1874 vs. 632). The required number of exercise sessions within 
the 24 weeks of the intervention program was 72. Patients showed 60.2±38.9 
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exercise sessions, 10.8±11.2 in training facilities. From T0 to T2, 24 patients 
(21.4%) showed ≥75% of required exercise sessions and showed regular 
attendance in supervised exercise sessions (see Table 5). 
Table 5: Patient-reported adherence by exercise log and weekly phone calls from T0 to T2 for 
totally analyzed numbers and separated for patients showing good adherence. 
 
 
 
 
T0 T2*  
Reported by 
exercise log 
Reported by 
weekly calls 
Totally analyzed, n% 
Exercise sessions, mean±SD (range) 
Exercise sessions in training center, mean±SD (range) 
 
72, 64.3% 
60.2±38.9 (0-158) 
10.8±11.2 (0-42) 
 
108, 96.4% 
41.0±23.9 (0-96) 
6.7±6.7 (0-21) 
Patients showing good adherence**, n % 
Exercise sessions, mean±SD (range) 
Exercise sessions in training center, mean±SD (range) 
24, 21.4% 
95.1±30.9 (55-158) 
19.5±10.1 (8-42) 
30, 26.8% 
68.5±12.6 (54-96) 
15.1±3.5 (8-12) 
*the evaluation is based on the total number of 112 enrolled EIP-patients, irrespective of drop-outs, 
deceased patients, and patients who were lost to follow up; 
**at least 54/72 (≥75% of required exercise sessions within 24 weeks) and at least 8/24 supervised 
exercise sessions in a local training facility. 
 
3.3.1.4 Endurance performance (6MWT) 
6MWT was completed by 95 patients and was prematurely terminated in four 
patients due to safety issues (dizziness, n=1; dyspnoea n=1) or other reasons 
(patient did not want to come to Heidelberg for performance assessment n=1; 
muscular pain in lower legs before 6MWT assessment, n=1). In 60 patients, the 
6MWT was not assessed according to safety issues (n=17), concerns of the 
patient (n=32), and other reasons (n=11). 
The range of percentage change in performance of the 6MWT was overall from -
39% to 142%. In total, 33.3% of patients declined in performance with a decline of 
≥10% in 10.4% of patients. Improvement in performance from T0 to T2 was 
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observed in 63.5% of patients with an increase of ≥10% in 33.3% of patients. As 
shown in Figure 4, more patients of the CMPC-arm performed both T0 and T2 
assessment of 6MWT overall improvement was higher in the EIP-arm. However, 
the highest increase of performance was observed in the CMPC-arm. In overall 
performance progression, both EIP- and CMPC-arm improved in 6MWT. 
Walk distance 
  
 
Figure 4: Percentage change (left) and overall performance progression (right) from T0 to T2 in 
walk distance of 6MWT for the EIP- and CMPC-arm. 
 
3.3.1.4.1 Intention-to-treat-analysis 
Data for measures at both time points were available for, in total 95 patients with 
46 patients of the EIP-arm and 49 patients of the CMPC-arm. Significant inner 
group improvement was observed in both the EIP-arm (483.2±100.2m vs. 
512.8±93.6m; adjusted mean change 30.1 95%CI 12.3, 47.8) and in the CMPC-
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arm (493.7±946.1m vs. 512.5±98.9m; adjusted mean change 17.6 95%CI 0.3, 
34.8). No significant between group differences were observed. The results are 
shown in Table 6. 
3.3.1.4.2 Subgroup analysis 
With regard to patients’ adherence of ≥75% and attendance in supervised exercise 
sessions (n=29), no significant between group or inner group differences were 
observed. The results are shown in Table 7. 
3.3.1.5 Strength performance (MVIC) 
Strength performance was assessed in 100 patients and was prematurely 
terminated in eleven patients due to safety issues (patient was not able to get in 
recumbent position for testing procedures, n=1), concerns of the patient (joint 
and/or muscle pain, n=3), and other reasons (joint and/or muscle pain, n=6; 
organisational flow, n=1). In 55 patients the MVIC was not assessed due to safety 
issues (newly diagnosed unstable bone metastases, n=5; acute bone fractures, 
n=3; pain, n=3; reduced condition/immobility, n=3; disease progression with 
unclear status on bone metastases, n=1; cardiovascular complications, n=1), 
concerns of the patient (n=27), and other reasons (n=12). 
The range of percentage change in performance of knee extension was from -34% 
to 87% and of elbow flexion from -52% to 61%. In total, 43.6% of patients declined 
in performance in knee extension with a decline of ≥10% in 22.8% of patients.  
Improvement in performance of knee extension from T0 to T2 was observed in 
56.4% of patients with an increase of ≥10% in 32.7% of patients. For elbow 
flexion, a decline in performance was observed in 43.2% of patients with a decline 
of ≥10% in 22.1% of patients. Improvement was observed in 52.6% of patients, 
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31.6% of patients showed an increase in performance of ≥10%. As shown in 
Figure 5, decline was lower and increase in performance was higher in the EIP-
arm. In overall performance progression, both EIP- and CMPC-arm improved in 
performance. In elbow flexion (Figure 6), patients of the CMPC-arm showed lower 
decline and higher increase in performance from T0 to T2. The performance of 
elbow flexion from T0 to T2 is identical in both study arms. 
Knee extension 
  
 
Figure 5: Percentage change (left) and overall performance progression (right) from T0 to T2 in 
knee extension (MVIC) for the EIP- and CMPC-arm. 
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Elbow flexion 
  
 
Figure 6: Percentage change (left) and overall performance progression (right) from T0 to T2 in 
elbow flexion (MVIC) for the EIP- and CMPC-arm. 
 
3.3.1.5.1 Intention-to-treat-analysis 
No significant between group differences were observed. Significant inner group 
improvement was observed in patients of the EIP-arm hip flexion. In the CMPC-
arm, significant inner group improvement was observed in hip abduction. The 
results are shown in Table 6. 
3.3.1.5.2 Subgroup analysis 
With regard to patients with adherence of ≥75% and attendance in supervised 
exercise sessions, significant between group differences were observed for hip 
flexion (p=.03). Significant inner group differences were observed in the EIP-arm in 
knee flexion and hip flexion. A significant inner group difference was also observed 
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in the CMPC-arm in hip abduction. With regard to patients with very limited and 
inadequate adherence no significant between group differences were observed 
from T0 to T2 (data not shown). The results are shown in Table 7. 
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Table 6: ANCOVA results of intention-to-treat analysis including physical performance parameter 
of MVIC from T0 to T2, adjusted on sex and age. 
Outcome Group n* 
T0 
Mean (SD) 
T2 
Mean (SD) 
Adjusted mean 
change (95CI) 
from T0 to T2 
Adjusted 
difference 
(95CI) between 
groups 
p(diff) 
        
BMI
A
 
 
EIP 66 24.9 (4.1) 24.9 (4.4) -0.0 (-0.5, 0.4) -0.3 (-0.9, 0.3) 0.33 
 CMPC 65 25.8 (4.6) 26.1 (5.1) 0.3 (-0.2, 0.7)   
Weight
B
 EIP 67 73.9 (13.5) 73.8 (14.7) 0.0 (-1.2, 1.3) -0.3 (-2.0, 1.5) 0.76 
 CMPC 65 77.6 (16.9) 78.1 (18.1) 0.3 (-0.9, 1.6)   
        
Walk distance
C 
EIP 46 483.2 (100.2) 512.8 (93.6) 30.1 (12.3, 47.8) 
12.5 (-12.4, 
37.4) 
0.32 
 CMPC 49 493.7 (96.1) 512.5 (98.9) 17.6 (0.3, 34.8)   
        
Knee flexion
D 
EIP 53 2.9 (0.8) 3.0 (0.8) 0.1 (-0.0, 0.3) 0.1 (-0.1, 0.3) 0.34 
 CMPC 47 2.8 (0.7) 2.9 (0.7) 0.0 (-0.1, 0.2)   
Knee extension
D 
EIP 53 4.5 (1.1) 4.7 (1.1) 0.2 (-0.0, 0.4) 0.2 (-0.1, 0.5) 0.18 
 CMPC 47 4.7 (1.0) 4.7 (1.1) -0.0 (-0.2, 0.2)   
Elbow flexion
D 
EIP 51 2.9 (0.6) 3.0 (0.7) 0.1 (-0.0, 0.2) 0.0 (-0.2, 0.2) 0.88 
 CMPC 43 2.9 (0.7) 3.0 (0.8) 0.1 (-0.1, 0.2)   
Elbow extension
D 
EIP 51 2.0 (0.5) 2.0 (0.5) 0.0 (-0.1, 0.1) -0.0 (-0.2, 0.1) 0.90 
 CMPC 42 2.0 (0.5) 2.1 (0.6) 0.0 (-0.1, 0.1)   
Hip abduction
D 
EIP 49 2.3 (0.4) 2.4 (0.5) 0.1 (-0.0, 0.2) -0.0 (-0.2, 0.1) 0.69 
 CMPC 47 2.2 (0.6) 2.4 (0.6) 0.1 (0.0, 0.3)   
Hip flexion
D 
EIP 45 2.2 (0.5) 2.4 (0.6) 0.2 (0.1, 0.4) 0.2 (-0.0, 0.4) 0.12 
 CMPC 44 2.2 (0.7) 2.3 (0.7) 0.1 (-0.1, 0.2)   
        
*number of patients with measures at both time points; presented data include dominant limbs only, 
A
in kg/m
2
; 
B
in kg; 
C
in m; 
D
in N/kg. 
 
Table 7: ANCOVA results of subgroup analysis including physical performance parameter of MVIC 
from T0 to T2 in EIP-patients with ≥75% adherence and supervised exercise sessions, adjusted on 
sex and age. 
Outcome Group n* 
T0 
Mean (SD) 
T2 
Mean (SD) 
Adjusted mean 
change (95CI) 
from T0 to T2 
Adjusted 
difference 
(95CI) between 
groups 
p(diff) 
        
Walk distance
C
 EIP+ 29 497.1 (84.4) 511.8 (85.7) 17.4 (-6.1, 41.0) 0.8 (-29.2, 30.8) 0.96 
 CMPC 49 493.7 (96.1) 512.5 (98.9) 16.6 (-1.5, 34.8)   
Knee flexion
D 
EIP+ 31 2.9 (0.8) 3.1 (0.9) 0.2 (0.0, 0.4) 0.2 (-0.0, 0.5) 0.08 
 CMPC 47 2.8 (0.7) 2.9 (0.7) 0.0 (-0.2, 0.2)   
Knee extension
D 
EIP+ 31 4.5 (1.2) 4.8 (1.0) 0.2 (-0.0, 0.5) 0.3 (-0.1, 0.6) 0.15 
 CMPC 47 4.7 (1.0) 4.7 (1.1) -0.0 (-0.2, 0.2)   
Elbow flexion
D 
EIP+ 30 2.9 (0.6) 3.1 (0.7) 0.2 (-0.0, 0.3) 0.1 (-0.2, 0.3) 0.49 
 CMPC 43 2.9 (0.7) 3.0 (0.8) 0.1 (-0.1, 0.2)   
Elbow extension
D 
EIP+ 30 2.0 (0.5) 2.1 (0.5) 0.1 (-0.1, 0.2) 0.0 (-0.1, 0.2) 0.63 
 CMPC 42 2.0 (0.5) 2.1 (0.6) 0.0 (-0.1, 0.1)   
Hip abduction
D 
EIP+ 29 2.3 (0.4) 2.4 (0.5) 0.1 (-0.0, 0.3) -0.0 (-0.2, 0.2) 0.79 
 CMPC 47 2.2 (0.6) 2.4 (0.6) 0.1 (0.0, 0.2)   
Hip flexion
D 
EIP+ 26 2.2 (0.5) 2.4 (0.7) 0.3 (0.1, 0.5) 0.2 (0.0, 0.5) 0.03 
 CMPC 44 2.2 (0.7) 2.3 (0.7) 0.1 (-0.1, 0.2)   
        
*number of patients with measures at both time points; EIP+: Patients of the EIP-arm with ≥75% 
adherence and regular exercise sessions in training facility; 
C
in m; 
D
in N/kg.  
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3.3.1.6 Treatment-related analysis 
In walk distance, increase was observed across almost all therapy regimens. In 
patients with radiotherapy only, sequentially radiotherapy, and TKIs the CMPC-
arm improved more compared to the EIP-arm. Patients with SCLC and 
consolidating radiotherapy improved in the EIP-arm while there was a percentage 
decrease in the CMPC-arm. In patients with chemotherapy only, the EIP-arm 
improved better compared to the CMPC-arm. In muscle strength of knee 
extension, patients of the EIP-arm with radiotherapy only, sequential or 
simultaneous radiotherapy, and chemotherapy only increased better than patients 
of the CMPC-arm. A very strong improve was observed for patients under 
immunotherapy. In patients with TKIs, the CMPC-arm improved better than the 
EIP-arm. In muscle strength of elbow flexion, the CMPC-arm increased higher 
across all therapy regimens except immunotherapy. Although patients with 
radiotherapy only of both study arms show percentage decrease, the decrease in 
the CMPC-arm was lower compared to the EIP-arm. Highest improve was 
observed for patients of the EIP-arm undergoing immunotherapy. See Figure 7.  
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RT only RT sequ RT sim TKI 
Consol RT 
(SCLC) 
Immuno- 
therapy 
CHT only 
Walk distance 
EIP, n 2 9 5 3 4 
 
23 
CMPC, n 2 5 6 4 8 
 
24 
Knee extension 
EIP, n 3 11 5 3 4 1 25 
CMPC, n 2 5 5 4 7 
 
24 
Elbow flexion 
EIP, n 3 11 5 3 5 1 25 
CMPC, n 2 4 5 4 7 
 
24 
         
 
Figure 7: Performance progression of endurance capacity (walk distance) and strength 
performance (knee extension, MVIC; elbow flexion, MVIC) with regard to treatment regimen RT 
(radiotherapy) only, RT sequ (sequentially), RT sim (simultaneously), TKI (tyrosine kinase 
inhibitors), consolidating radiotherapy in SCLC (Small Cell Lung Cancer), immunotherapy, and 
CHT (chemotherapy) only from T0 to T2 and corresponding number of patients of EIP- and CMPC-
arm. 
 
3.3.1.7 Regression analysis 
The regression analysis included T2 performance of 6MWT (walk distance) and 
MVIC (knee extension, elbow flexion). In demographic variables, significant 
correlations were observed in 6MWT for patients ≤62 years (p<.05) and for knee 
extension in patients with a BMI of 20-25 kg/m2 (p<.05). In elbow flexion 
performance was significantly correlated with male sex (p<.01), age ≤62 years 
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(p<.01), and BMI 20-25 kg/m2 (p<.01). Disease-related variables indicated no 
correlation with performance of 6MWT and elbow flexion. In knee extension, 
patients with radiotherapy alone performed significantly worse compared to 
patients with chemotherapy alone (p<.05). No correlations were observed in 
patients who had been physically active before diagnosis. Adherence to the EIP 
program did not correlate with physical performance parameter. The regression 
analysis is presented in Table 8. 
3.3.1.8 Additional parameter 
The ITT-analysis also included body weight (in kg) and BMI (in kg/m2) from T0 to 
T2. There were no significant inner group or between group differences observed. 
In the EIP- and CMPC-arm, BMI remained stable. Body weight remained stable in 
the EIP-arm (73.9±13.5 vs. 73.8±14.7) and slightly increased in the CMPC-arm 
(77.6±16.9 vs. 78.1±18.1). The results are shown in Table 6.  
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Table 8: Results of multiple regression analysis of strength performance (knee extension, elbow 
flexion) and endurance capacity (6-Minute walk distance) in correlation to sex, age, body mass 
index, smoking status, lung cancer histology, upfront radio-chemotherapy, days between enrolment 
and date of first diagnosis, metastatic status, sports/exercise history at T2. 
 
 
Meter 
 
 
Knee 
extension 
 
 
Elbow 
flexion 
 
 
 
 R
2
=.47  R
2
=.44  R
2
=.59  
 
 Beta
A 
p Beta
A 
p Beta
A 
p 
        
Sex 
 
male 
female 
33.58 
reference 
 0.40 
reference 
 0.71 
reference 
** 
        
Age ≤62 yrs. 
>62 yrs. 
70.94 
reference 
* 0.50 
reference 
 0.60 
reference 
** 
        
BMI <20 kg/m
2 
20-25 kg/m
2 
≥25 kg/m
2 
16.89 
41.83 
reference 
 0.51 
1.00 
reference 
 
* 
0.13 
0.60 
reference 
 
** 
        
Sports/exercise 
before diagnosis 
Yes 
No 
-24.34 
reference 
 0.16 
reference 
 
 
-0.13 
reference 
 
        
Days since study 
enrolment 
≥48 days 
<48 days 
25.00 
reference 
 -0.18 
reference 
 -0.11 
reference 
 
        
Advanced disease Yes 
No 
19.25 
reference 
 -0.46 
reference 
 -0.16 
reference 
 
        
Therapy RT alone 
RCHT, sequentially 
RCHT, simultaneously 
TKI 
Consolidating RT
C 
CHT alone 
-80.23 
32.94 
68.47 
112.92 
9.35 
reference 
 
 
 
() 
-1.77 
-0.76 
-0.23 
0.73 
-0.59 
reference 
* -0.91 
-0.26 
-0.11 
-0.46 
-0.48 
reference 
 
        
Adherence
B 
(EIP-arm only) 
Good 
Limited 
Inadequate 
-8.58 
1.35 
reference 
 0.07 
-0.64 
reference 
 0.02 
-0.31 
reference 
 
        
A 
Regression coefficient from multiple regression model, all variables were included simultaneously 
in the model; () trend (p<0.07); * p<.05; **p<.01; ***<.0001; 
B
Good (>75% of required exercise 
sessions and regular supervised exercise sessions); Limited (30-75% of required exercise 
sessions); Inadequate (<30% of required exercise sessions); 
C
in SCLC patients; RT: radiotherapy; 
sequ: sequentially, sim: simultaneously, TKI: tyrosine kinase inhibitors, CHT: chemotherapy. 
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3.3.2 Part 2A: Intervention results from T0 to T1 
3.3.2.1 Patient adherence (T0-T1) 
The exercise intervention was performed by 103 patients (92.0%) of the EIP-arm 
from baseline (T0) to week 12 (T1). One patient withdrew from participation before 
baseline assessment and eight patients did not start the exercise intervention due 
to being overwhelmed and/or exhausted (n=4) and treatment-related side-effects 
(n=4). One patient started the exercise intervention in week 10 due to treatment-
related side-effects. With regard to the performed exercise sessions, fifty-six 
patients (53.8%) showed good adherence, 26 patients (25.0%) showed limited and 
twenty-two patients (21.2%) showed inadequate adherence. Sixty-two patients 
(59.6%) exercised regularly supervised in training facilities near their home-town 
(n=61) and one patients exercise supervised with a personal coach (n=1). Thirty-
nine patients (34.8%) exercised home-based only. Eight patients (7.1%) were not 
able to get to the training facility and for three patients (2.7%) there was no training 
facility in their hometown available. Weekly exercise sessions within the previous 
week were reported by the patients within the weekly phone calls. Additionally, 
patients reported their exercise sessions weekly in standardized exercise logs. 
3.3.2.1.1 Adherence according to weekly patient-reported information 
via CMPC 
The exercise intervention could not be started by 10 patients (8.9%) due to 
treatment-related side-effects. Within the first 12 weeks, 14 patients prematurely 
terminated the exercise intervention due to treatment-related side-effects (n=6), 
lost-to-follow-up (n=3), or death (n=5). The minimum number of required exercise 
sessions within the first 12 weeks of the intervention program was 36. Patients 
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showed 21.3±11.3 exercise sessions, 3.1±3.2 in training facilities. Twenty-six 
patients (23.2%) showed ≥75% of required exercise sessions and exercised 
regularly supervised (see Table 9). 
3.3.2.1.2 Intervention uptake and completion rates according to 
exercise log 
Within the first 12 weeks of the intervention, patients performed 2464 exercise 
sessions with an average Borg level of 13 (range 5-19). At least 395 exercise 
sessions were performed in a training facility. Patients showed 34.1±20.1 exercise 
sessions, 5.4±5.4 in training facilities. Twenty-seven patients (24.1%) showed 
≥75% of required exercise sessions and exercised regularly supervised in training 
facilities (see Table 9). 
With regard to the number of weekly exercise sessions of the patients of the EIP-
arm, patients exercised most from week 2 to week 5. Afterwards, we observed a 
decline in the number of exercise sessions until week 12. The allocation of the 
type of exercise showed that patients preferred rather resistance and combined 
training sessions instead of endurance training sessions. From week 8 to week 11, 
the allocation is even in resistance, endurance and combined training sessions 
(see Figure 8). 
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Table 9: Patient-reported adherence by exercise log and weekly phone calls from T0 to T1 for 
totally analyzed numbers and separated for patients showing good adherence. 
T0 T1* 
Reported by 
exercise log 
Reported by 
weekly calls 
Totally analyzed, n% 
Exercise sessions, mean±SD (range) 
Exercise sessions in training center, mean±SD (range) 
73, 65.2% 
34.1±20.1 (0-72) 
5.4±5.4 (0-21) 
108, 96.4% 
21.3±11.3 (0-49) 
3.1±3.2 (0-10) 
Patients showing good adherence**, n % 
Exercise sessions, mean±SD (range) 
Exercise sessions in training center, mean±SD (range) 
27, 24.1% 
47.4±14.6 (27-72) 
10±4.0 (4-21) 
26, 23.2% 
33.7±5.8 (27-47) 
6.9±2.0 (4-10) 
*the evaluation is based on the total number of 112 enrolled EIP-patients, irrespective of drop-outs, 
deceased patients, and patients who were lost to follow up; 
**at least 27/36 (≥75% of required exercise sessions within 12 weeks) and at least 4/12 supervised 
exercise sessions in a local training facility. 
 
 
Figure 8: Exercise sessions performed by EIP-arm patients from T0 to T1 regarding weekly uptake 
of resistance, endurance and combined resistance and endurance exercise sessions. 
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patients 6MWT was not assessed due to safety issues (immobility, n=3; reduced 
condition, n=3; newly diagnosed unstable bone metastases, n=2; cardiac 
complications, n=1; surgery, n=1), concerns of the patient (n=17), and other 
reasons (n=10). 
The range of percentage change in performance of the 6MWT was from -53% to 
168%. In total, 40.3% of patients declined in performance with a decline of ≥10% 
in 9.4% of patients.  Improvement in performance was observed in 57.7% of 
patients with an increase of ≥10% in 24.8% of patients. As shown in Figure 9, 
more patients of the EIP-arm performed T0 and T1 assessment for 6MWT. 
Overall, patients of both study arms improved performance. 
 
Figure 9: Percentage change from T0 T1 in walk distance of 6MWT in EIP- and CMPC-arm. 
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3.3.2.2.1 Intention-to-treat-analysis 
Data for measures at both time points were available for 79 patients of the EIP-
arm and 70 patients of the CMPC-arm. Significant improvement was observed in 
both the EIP-arm (464.9±94.0m vs. 478.9±98.1m; adjusted mean change 14.4 
95%CI 2.5, 26.2) and in the CMPC-arm (496.0±88.9m vs. 510.3±82.5m; adjusted 
mean change 18.2 95%CI 5.6, 30.8). No significant between group differences 
were observed. The results are shown in Table 10. 
3.3.2.2.2 Subgroup analysis 
With regard to patients’ adherence of ≥75% and attendance in supervised exercise 
sessions (n=43), no significant between group differences were observed. 
Significant improvement was observed in the CMPC-arm (496.0±88.9m vs. 
510.3±82.5m; adjusted mean change 16.0 95%CI 4.0, 28.0) and in the EIP-arm 
(484.7±81.0m vs. 502.2±79.6m; adjusted mean change 18.3 95%CI 3.1, 33.6). No 
significant between group differences were observed. The results are shown in 
Table 11. 
3.3.2.3 Strength performance (MVIC) 
The MVIC was assessed in 146 patients and was prematurely terminated in seven 
patients due to concerns of the patient (patient was not able to get in recumbent 
position for testing procedures, n=1; other: n=1), complications with handheld-
device (n=1), organisational flow (n=3), and other (n=1). In forty-five patients, the 
MVIC was not assessed in order to safety issues (pain, n=3; reduced condition, 
n=3; unstable bone metastases, n=2; surgery, n=1; cardiac complications, n=1; 
other, n=2), concerns of the patient (n=18), and other reasons (n=13). 
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The range of percentage change in performance of knee extension was from -50% 
to 85% and of elbow flexion from -38% to 84%. In total, 54.1% of patients declined 
in performance in knee extension with a decline of ≥10% in 26.7% of patients.  
Improvement in performance of knee extension from T0 to T1 was observed in 
43.8% of patients with an increase of ≥10% in 32.2% of patients. For elbow 
flexion, a decline in performance was observed in 44.4% of patients with a decline 
of ≥10% in 20.0% of patients. Improvement was observed in 54.1% of patients, 
25.9% of patients showed an increase in performance of ≥10%. As shown in 
Figure 10, percentage deviation of knee extension in performance was lower in 
decline and higher in increase in the EIP-arm. In elbow flexion (Figure 11), 
performance improved higher in the CMPC-arm. 
 
Figure 10: Percentage change from T0 T1 in knee extension of MVIC in EIP- and CMPC-arm. 
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Figure 11: Percentage change from T0 T1 in elbow flexion of MVIC in EIP- and CMPC-arm. 
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exercise. With regard to patients (n=4) showing very limited and inadequate 
adherence to the exercise program (<30% of required exercise sessions and no 
supervised exercise sessions) due to treatment-related side-effects and 
reduced/bad condition, the results show significant between group differences in 
elbow flexion (p=.02), elbow extension (p<.01), and hip flexion (p=.03) of the EIP-
arm compared to consistent performance in the CMPC-arm. Significant inner 
group decline was observed in the EIP-arm in knee extension, elbow flexion, 
elbow extension, and hip flexion. The results are shown in Table 11. 
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Table 10: ANCOVA results of intention-to-treat analysis including physical performance parameter 
of MVIC from T0 to T1, adjusted on sex and age. 
        
Outcome Group n* 
T0 
Mean (SD) 
T1 
Mean (SD) 
Adjusted mean 
change (95CI) 
from T0 to T1 
Adjusted 
difference 
(95CI) between 
groups 
p(diff) 
        
BMI
A 
EIP 91 25.0 (4.4) 25.1 (4.6) 0.1 (-0.2, 0.4) 0.0 (-0.4, 0.5) 0.84 
 CMPC 82 25.3 (4.6) 25.4 (4.9) 0.0 (-0.3, 0.4)   
Weight
B 
EIP 91 74.3 (15.3) 74.4 (15.9) 0.2 (-0.7, 1.0) 0.3 (-0.9, 1.5) 0.65 
 CMPC 83 76.7 (16.6) 76.7 (17.3) -0.1 (-1.0, 0.8)   
        
Walk distance
C
 EIP 79 464.9 (94.0) 478.9 (98.1) 14.4 (2.5, 26.2) -3.9 (-21.2, 13.5) 0.66 
 CMPC 70 496.0 (88.9) 510.3 (82.5) 18.2 (5.6, 30.8)   
        
Knee flexion
D 
EIP 77 2.9 (0.7) 3.0 (0.7) 0.1 (-0.0, 0.2) 0.1 (-0.0, 0.3) 0.18 
 CMPC 69 2.9 (0.7) 2.9 (0.7) -0.1 (-0.2, 0.1)   
Knee extension
D 
EIP 77 4.4 (1.1) 4.6 (1.1) 0.1 (-0.0, 0.3) 0.3 (0.1, 0.6) 0.02 
 CMPC 69 4.6 (1.0) 4.4 (1.1) -0.2 (-0.4, 0.0)   
Elbow flexion
D 
EIP 73 3.0 (0.7) 3.0 (0.6) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.2) 0.73 
 CMPC 62 2.9 (0.7) 2.9 (0.7) -0.0 (-0.1, 0.1)   
Elbow extension
D 
EIP 71 2.0 (0.5) 2.1 (0.5) -0.0 (-0.1, 0.1) -0.1 (-0.2, 0.1) 0.32 
 CMPC 62 2.0 (0.6) 2.0 (0.6) 0.1 (-0.0, 0.1)   
Hip abduction
D
 EIP 74 2.3 (0.4) 2.3 (0.5) 0.1 (-0.0, 0.2) 0.0 (-0.1, 0.2) 0.56 
 CMPC 68 2.2 (0.6) 2.3 (0.5) 0.0 (-0.1, 0.1)   
Hip flexion
D
 EIP 69 2.1 (0.6) 2.2 (0.7) 0.1 (0.0, 0.2) 0.1 (-0.0, 0.3) 0.09 
 CMPC 65 2.2 (0.7) 2.2 (0.7) -0.0 (-0.1, 0.1)   
        
*number of patients with measures at both time points; presented data include dominant limbs only, 
A
in kg/m
2
; 
B
in kg; 
C
in m; 
D
in N/kg. 
 
Table 11: ANCOVA results of subgroup analysis including physical performance parameter of 
MVIC from T0 to T1 in EIP-patients with ≥75% adherence and supervised exercise sessions, 
adjusted on sex and age. 
Outcome Group n* 
T0 
Mean (SD) 
T1 
Mean (SD) 
Adjusted mean 
change(95CI) 
from T0 to T1 
Adjusted 
difference 
(95CI) between 
groups 
p(diff) 
        
Walk distance
C
 EIP+ 43 484.7 (81.0) 502.2 (79.6) 18.3 (3.1, 33.6) 2.3 (-17.1, 21.8) 0.81 
 CMPC 70 496.0 (88.9) 510.3 (82.5) 16.0 (4.0, 28.0)   
Knee flexion
D 
EIP+ 44 2.8 (0.7) 3.1 (0.7) 0.2 (0.1, 0.4) 0.3 (0.1, 0.4) <.01 
 CMPC 69 2.9 (0.7) 2.9 (0.7) -0.1 (-0.2, 0.0)   
Knee extension
D 
EIP+ 44 4.4 (1.2) 4.8 (1.2) 0.4 (0.1, 0.6) 0.5 (0.2, 0.9) <.01 
 CMPC 69 4.6 (1.0) 4.4 (1.1) -0.2 (-0.4, 0.0)   
Elbow flexion
D 
EIP+ 43 2.9 (0.6) 3.0 (0.6) 0.1 (0.0, 0.3) 0.1 (-0.0, 0.3) 0.09 
 CMPC 62 2.9 (0.7) 2.9 (0.7) -0.0 (-0.1, 0.1)   
Elbow extension
D 
EIP+ 43 2.0 (0.5) 2.1 (0.5) 0.1 (-0.0, 0.2) 0.0 (-0.1, 0.2) 0.59 
 CMPC 62 2.0 (0.6) 2.0 (0.6) 0.1 (-0.0, 0.2)   
Hip abduction
D
 EIP+ 43 2.3 (0.4) 2.4 (0.5) 0.1 (0.0, 0.3) 0.1 (-0.0, 0.3) 0.16 
 CMPC 68 2.2 (0.6) 2.3 (0.5) 0.0 (-0.1, 0.1)   
Hip flexion
D
 EIP+ 40 2.1 (0.5) 2.3 (0.6) 0.2 (0.1, 0.3) 0.2 (0.1, 0.4) <.01 
 CMPC 65 2.2 (0.7) 2.2 (0.7) -0.0 (-0.1, 0.1)   
        
*number of patients with measures at both time points; EIP+: patients with ≥75% adherence and 
regular exercise sessions in training facility; 
C
in m; 
D
in N/kg 
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3.3.2.4 Treatment-related analysis 
In walk distance an increase in performance was observed in patients receiving 
radiotherapy only. However, the increase in the CMPC-arm was higher compared 
to the increase in the EIP-arm. A slight increase in both study arms was observed 
for patients undergoing sequentially and simultaneously radiotherapy and 
treatment with tyrosine kinase inhibitors. For muscle strength in knee extensors an 
increase in the EIP-arm was observed while there was a decrease in the CMPC-
arm in patients with radiotherapy only. Overall, there was higher increase in the 
EIP-arm in patients with sequentially and simultaneously radiotherapy. In patients 
under TKI therapy, the increase was higher in the CMPC-arm. For patients with 
SCLC receiving consolidating radiotherapy, there was a decrease observed in 
both study arms in knee extension. Similar results were observed for muscle 
strength in elbow flexion. For patients receiving chemotherapy only, which was the 
largest group in treatment, lowest percentage change was observed for both walk 
distance and strength capacity (see Figure 12). 
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RT only RT sequ RT sim TKI 
Consol RT 
(SCLC) 
Immuno- 
therapy 
CHT only 
Walk distance 
EIP, n 3 10 9 4 10  44 
CMPC, n 3 8 7 4 9  41 
Knee extension 
EIP, n 3 11 8 4 9 1 41 
CMPC, n 3 8 7 4 9  38 
Elbow flexion 
EIP, n 3 11 8 4 8 1 40 
CMPC, n 2 6 7 4 9  37 
         
 
Figure 12: Performance progression of endurance capacity (walk distance) and strength 
performance (knee extension, MVIC; elbow flexion, MVIC) with regard to treatment regimen RT 
(radiotherapy) only, RT sequ (sequentially), RT sim (simultaneously), TKI (tyrosine kinase 
inhibitors), consolidating radiotherapy in SCLC (Small Cell Lung Cancer), immunotherapy, and 
CHT (chemotherapy) only from T0 to T1 and corresponding number of patients of EIP- and CMPC-
arm. 
 
3.3.2.5 Regression analysis 
The regression analysis included T1 performance of 6MWT and MVIC (knee 
extension, elbow flexion). In demographic variables, significant correlations were 
observed in 6MWT for patients ≤62 years (p<.0001). Men performed significantly 
better than women in knee extension (p<.05) and elbow flexion (p<.0001). 
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Diagnose-related variables indicated no correlation with performance of 6MWT 
and knee extension. In elbow flexion, patients with diagnosis ≥48 days performed 
significantly worse compared to patients with diagnosis <48 days (p<.05) and 
patients with metastatic disease at study enrolment performed significantly worse 
in elbow flexion compared to patients with non-metastatic disease (p<.05). 
Patients with limited adherence to the EIP program performed significantly worse 
in knee extension compared to patients with inadequate adherence (p<.05). No 
correlations were observed in patients who had been physically active before 
diagnosis. The complete regression analysis is presented in Table 12. 
3.3.2.6 Additional parameter 
The ITT-analysis also included body weight (in kg) and BMI (in kg/m2) from T0 to 
T1. There were no significant inner group or between group differences observed. 
BMI and body weight remained stable in both study arms. The results are shown 
in Table 10. 
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Table 12: Results of multiple regression analysis of strength performance (knee extension, elbow 
flexion) and endurance capacity (6-minute walk distance) in correlation to sex, age, body mass 
index, smoking status, lung cancer histology, upfront radio-chemotherapy, days between enrolment 
and date of first diagnosis, metastatic status, sports/exercise history at T1. 
 
 
Meter 
 
 
Knee 
extension 
 
 
Elbow 
flexion 
 
 
 
 R
2
=.40  R
2
=.40  R
2
=.45  
  Beta
A 
p Beta
A
 p Beta
A
 p 
Sex 
 
male 
female 
25.05 
reference 
 
 
0.50 
reference 
* 0.62 
reference 
*** 
Age ≤62 yrs. 
>62 yrs. 
88.44 
reference 
*** 
 
0.30 
reference 
 0.05 
reference 
 
BMI <20 kg/m
2 
20-25 kg/m
2 
≥25 kg/m
2 
-7.60 
28.36 
reference 
 0.50 
0.57 
reference 
 -0.07 
0.36 
reference 
 
() 
        
Sports/exercise 
before diagnosis 
Yes 
No 
-39.55 
reference 
 -0.23 
reference 
 
 
0.10 
reference 
 
Days since study 
enrolment 
≥48 days 
<48 days 
-3.72 
reference 
 -0.34 
Reference 
 -0.32 
reference 
* 
Advanced disease Yes 
No 
16.93 
reference 
 -0.44 
reference 
 -0.43 
reference 
* 
        
Therapy RT alone 
RCHT, sequentially 
RCHT, simultaneously 
TKI 
Consolidating RT 
CHT alone 
-41.57 
38.13 
59.20 
60.27 
-0.50 
reference 
 -0.68 
0.90 
0.30 
1.00 
-0.76 
reference 
 
 
 
() 
-0.08 
-0.26 
0.04 
0.14 
0.45 
reference 
 
        
Adherence
B 
(EIP-arm only) 
Good 
Limited 
Inadequate 
33.88 
0.29 
reference 
 -0.06 
-0.98 
reference 
 
* 
0.03 
-0.52 
reference 
 
() 
        
A 
Regression coefficient from multiple regression model, all variables were included simultaneously 
in the model; () trend (p<0.07); * p<.05; **p<.01; ***<.0001; 
B
Good (>75% of required exercise 
sessions and regular supervised exercise sessions); Limited (30-75% of required exercise 
sessions); Inadequate (<30% of required exercise sessions). 
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3.3.3 Part 2B: Intervention results from T1 to T2 
3.3.3.1 Patient adherence (T1-T2) 
From T1 to T2, four patients (3.6%) withdrew from participation after T1 
assessment and thirteen patients (11.6%) were not able to continue the exercise 
intervention due to and treatment-related side-effects and/or disease progression. 
One patient was lost to follow up after T1. Fifty-two patients (46.4%) exercised 
regularly supervised in training facilities near their home-tow. Forty-two patients 
(37.5%) exercised home-based only. Weekly exercise sessions within the last 
week were reported by the patients within the weekly phone calls. Additionally, 
patients reported their exercise sessions weekly in standardized exercise logs. 
3.3.3.1.1 Intervention uptake and completion rates according to 
weekly patient-reported information via CMPC (weekly phone calls) 
Adherence was evaluated for 98 patients (85.2%) of the EIP-arm. The minimum 
number of required exercise sessions within the second 12 weeks of the 
intervention program was 36. Patients showed 19.7±14.6 exercise sessions, 
3.6±4.2 in training facilities. Thirty-three patients (29.5%) showed ≥75% of 
required exercise sessions and showed regular attendance in supervised exercise 
sessions (see Table 13). 
3.3.3.1.2 Intervention uptake and completion rates according to 
exercise log 
From T1 to T2, patients performed 1618 exercise sessions at an average Borg 
level of 13 (range 8-19). Patients performed 319 exercise sessions in training 
facilities. 
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Patients showed 25.3±20.1 exercise sessions, 5.0±6.0 in training facilities. 
Twenty-one patients (18.8%) showed ≥75% of required exercise sessions and 
exercised regularly supervised (see Table 13). With regard to the number of 
weekly exercise sessions of the patients of the EIP-arm, patients exercised overall 
less compared to the first 12 weeks of the intervention. With regard to the second 
12 weeks though, exercise sessions rates were highest between weeks 12 and 
16. Afterwards, there was a decline in the number of exercise sessions until week 
24. The allocation of the type of exercise showed that patients preferred rather 
endurance and combined training sessions instead of resistance training sessions 
(see Figure 13). 
Table 13: Patient-reported adherence by exercise log and weekly phone calls from T1 to T2 for 
totally analyzed numbers and separated for patients showing good adherence. 
T1 T2* 
Reported by 
exercise log 
Reported by 
weekly calls 
Totally analyzed, n% 
Exercise sessions, mean±SD (range) 
Exercise sessions in training center, mean±SD (range) 
64, 57.1% 
25.3±20.1 (0-76) 
5.0±6.0 (0-24) 
108, 96.4% 
19.7±14.6 (0-49) 
3.6±4.2 (0-13) 
Patients showing good adherence**, n % 
Exercise sessions, mean±SD (range) 
Exercise sessions in training center, mean±SD (range) 
21, 18.8% 
48.0±14.8 (28-76) 
11.8±6.2 (5-24) 
33, 29.5% 
36.8±7.0 (27-49) 
8.5±2.7 (4-13) 
*the evaluation is based on the total number of 112 enrolled EIP-patients, irrespective of drop-outs, 
deceased patients, and patients who were lost to follow up; 
**at least 27/36 (≥75% of required exercise sessions within 12 weeks) and at least 4/12 supervised 
exercise sessions in a local training facility. 
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Figure 13: Exercise sessions performed by EIP-arm patients from T1 to T2 regarding weekly 
uptake of resistance, endurance and combined resistance and endurance exercise sessions. 
 
3.3.3.2 Endurance performance (6MWT) 
6MWT was completed by 89 patients at both T1 and T2. 
3.3.3.2.1 Intention-to-treat-analysis 
Data for measures at both time points were available for 46 patients of the EIP-
arm and 43 patients of the CMPC-arm. No significant between group or inner 
group differences were observed. The results show a slight increase in the EIP-
arm (505.2±87.3 vs. 512.8±93.6m) and a slight decrease in the CMPC-arm 
(527.7±85.1 vs. 521.3±99.4m). The results are shown in Table 14. 
The range of percentage change in performance of the 6MWT was from -42% to 
23%. In total, 41.1% of patients declined in performance with a decline of ≥10% in 
14.4% of patients. Improvement in performance from T1 to T2 was observed in 
50.0% of patients with an increase of ≥10% in 18.9% of patients. 
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3.3.3.2.2 Subgroup analysis 
With regard to patients’ adherence of ≥75% and attendance in supervised exercise 
sessions (n=29), no significant between group or inner group differences were 
observed. The results are shown in Table 15. 
3.3.3.3 Strength performance (MVIC) 
The MVIC was assessed by 94 patients at both T1 and T2. The range of 
percentage change in performance of knee extension was from -36% to 60% and 
of elbow flexion from -52% to 61%. In total, 50.0% of patients declined in 
performance in knee extension with a decline of ≥10% in 23.2% of patients. 
Improvement in performance of knee extension from T1 to T2 was observed in 
50.5% of patients with an increase of ≥10% in 45.3% of patients. For elbow 
flexion, a decline in performance was observed in 44.6% of patients with a decline 
of ≥10% in 16.3% of patients. Improvement was observed in 50.0% of patients, 
28.3% of patients showed an increase in performance of ≥10%. 
3.3.3.3.1 Intention-to-treat-analysis 
Significant between group differences from T1 to T2 were not observed. 
Significant inner group improvement was observed in patients of the CMPC-arm in 
hip abduction. The results are shown in Table 14. 
3.3.3.3.2 Subgroup analysis 
With regard to patients with adherence of ≥75% and attendance in supervised 
exercise sessions, no significant between or inner group differences were 
observed. For patients with very limited and inadequate adherence (<30%), no 
significant between group differences were observed. The results are shown in 
Table 15.  
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Table 14: ANCOVA results of intention-to-treat analysis including physical performance parameter 
of MVIC from T1 to T2, adjusted on sex and age. 
Outcome Group n* 
T1 
Mean (SD) 
T2 
Mean (SD) 
Adjusted mean 
change(95CI) from 
T1 to T2 
Adjusted 
difference 
(95CI) between 
groups 
p(diff) 
        
BMI
A 
EIP 64 25.0 (4.4) 24.9 (4.4) -0.1 (-0.4, 0.2) -0.3 (-0.8, 0.1) 0.18 
 CMPC 59 26.1 (5.1) 26.3 (5.2) 0.2 (-0.1, 0.5)   
Weight
B 
EIP 65 74.3 (15.0) 74.0 (14.9) -0.3 (-1.2, 0.6) -0.7 (-2.0, 0.6) 0.26 
 CMPC 60 77.9 (18.3) 78.4 (18.7) 0.4 (-0.5, 1.3)   
        
Walk distance
C 
EIP 46 505.2 (87.3) 512.8 (93.6) 7.2 (-6.6, 21.1) 16.1 (-4.0, 36.1) 0.11 
 CMPC 43 527.7 (85.1) 521.3 (99.4) -8.9 (-23.2, 5.5)   
        
Knee flexion
D 
EIP 52 3.1 (0.7) 3.0 (0.8) -0.0 (-0.2, 0.1) -0.0 (-0.2, 0.2) 0.94 
 CMPC 42 2.9 (0.7) 3.0 (0.7) -0.0 (-0.2, 0.1)   
Knee extension
D 
EIP 52 4.7 (1.1) 4.7 (1.1) 0.0 (-0.2, 0.2) -0.1 (-0.4, 0.2) 0.66 
 CMPC 42 4.5 (1.2) 4.7 (1.1) 0.1 (-0.1, 0.3)   
Elbow flexion
D 
EIP 51 3.0 (0.6) 3.1 (0.7) 0.0 (-0.1, 0.1) -0.1 (-0.3, 0.1) 0.29 
 CMPC 40 3.0 (0.7) 3.1 (0.8) 0.1 (-0.0, 0.3)   
Elbow extension
D 
EIP 51 2.1 (0.4) 2.0 (0.5) -0.0 (-0.1, 0.1) 0.0 (-0.1, 0.2) 0.61 
 CMPC 39 2.1 (0.6) 2.1 (0.6) -0.1 (-0.2, 0.0)   
Hip abduction
D 
EIP 50 2.4 (0.5) 2.4 (0.5) -0.0 (-0.1, 0.1) -0.1 (-0.3, 0.0) 0.13 
 CMPC 42 2.3 (0.6) 2.5 (0.6) 0.1 (0.0, 0.2)   
Hip flexion
D 
EIP 47 2.4 (0.7) 2.4 (0.7) 0.1 (-0.1, 0.2) 0.1 (-0.1, 0.3) 0.32 
 CMPC 41 2.3 (0.7) 2.3 (0.7) -0.0 (-0.1, 0.1)   
        
*number of patients with measures at both time points; presented data include dominant limbs only, 
A
in kg/m
2
; 
B
in kg; 
C
in m; 
D
in N/kg. 
Table 15: ANCOVA results of subgroup analysis including physical performance parameter of 
MVIC from T1 to T2 in EIP-patients with ≥75% adherence and supervised exercise sessions, 
adjusted on sex and age. 
Outcome Group n* 
T1 
Mean (SD) 
T2 
Mean (SD) 
Adjusted mean 
change(95CI) from 
T1 to T2 
Adjusted 
difference 
(95CI) between 
groups 
p(diff) 
        
Walk distance
C
 EIP+ 29 510.9 (79.5) 511.8 (85.7) 0.8 (-17.2, 18.9) 
10.0 (-13.5, 
33.6) 
0.40 
 CMPC 43 527.7 (85.1) 521.3 (99.4) -9.2 (-24.1, 5.6)   
        
Knee flexion
D 
EIP+ 31 3.1 (0.7) 3.1 (0.9) 0.0 (-0.2, 0.2) 0.1 (-0.2, 0.3) 0.55 
 CMPC 42 2.9 (0.7) 3.0 (0.7) -0.0 (-0.2, 0.1)   
Knee extension
D 
EIP+ 31 4.8 (1.2) 4.8 (1.0) 0.0 (-0.2, 0.2) -0.1 (-0.4, 0.2) 0.66 
 CMPC 42 4.5 (1.2) 4.7 (1.1) 0.1 (-0.1, 0.3)   
Elbow flexion
D 
EIP+ 30 3.1 (0.6) 3.1 (0.7) 0.0 (-0.2, 0.2) -0.1 (-0.3, 0.1) 0.31 
 CMPC 40 3.0 (0.7) 3.1 (0.8) 0.1 (-0.0, 0.3)   
Elbow extension
D 
EIP+ 30 2.1 (0.4) 2.1 (0.5) -0.0 (-0.2, 0.1) 0.0 (-0.1, 0.2) 0.60 
 CMPC 39 2.1 (0.6) 2.1 (0.6) -0.1 (-0.2, 0.0)   
Hip abduction
D 
EIP+ 29 2.4 (0.5) 2.4 (0.5) 0.0 (-0.1, 0.2) -0.1 (-0.3, 0.1) 0.37 
 CMPC 42 2.3 (0.6) 2.5 (0.6) 0.1 (-0.0, 0.2)   
Hip flexion
D 
EIP+ 27 2.5 (0.8) 2.5 (0.8) 0.1 (-0.1, 0.2) 0.1 (-0.1, 0.3) 0.37 
 CMPC 41 2.3 (0.7) 2.3 (0.7) -0.0 (-0.2, 0.1)   
        
*number of patients with measures at both time points; EIP-good: ≥75% adherence and regular 
exercise sessions in training facility; 
C
in m; 
D
in N/kg. 
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4. Discussion 
The intention of this work was to provide a holistic presentation of the analyses 
elaborated in the course of this dissertation. This included previously published 
results of a literature review on physical exercise in patients with advanced cancer 
[102], the design paper of the POSITIVE study (Part III) [109], a cross-sectional 
report of baseline data of the POSITIVE study (Part III) including exercise behavior 
and physical performance in patients with advanced lung cancer [101], and the 
intervention analyses of the 24-week physical exercise program of the POSITIVE 
study (Part III) (in preparation). 
4.1 Main findings 
Previously, the field of physical exercise in patients with advanced cancer and in 
particularly lung cancer was found to be extremely understudied. Now, an 
increasing number of exercise intervention trials in the lung cancer continuum 
exists including RCTs in the non-operable setting. However, consistent evidence is 
still lacking. The results differ from what has been observed and demonstrated for 
example in breast cancer, so far. Yet, studies in the lung cancer continuum that 
provide consistent evidence are still pending. 
From the current literature including patients with advanced cancer no specific 
guidelines or recommendations have been established. The implemented physical 
exercise interventions varied in each trial: the programs included resistance 
training, supervised circuit training, home videotape seated exercise program, and 
structured physical therapy. However, it has been shown that patients benefit from 
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exercise programs physically and mentally. Although there was large 
inconsistency regarding contents, durations, types, and intensities in the exercise 
intervention programs, the beneficial impact for patients has been demonstrated. 
In the cross-sectional analyses of baseline data, the observed findings showed 
clear differences in physical exercise and walking behavior shortly after diagnosis 
compared to the year before diagnosis. A strong decline in sports/exercise 
participation and low physical exercise levels shortly after first diagnosis were 
observed. The recommended amount of 150 minutes per week was only met by 
less than a third of participants in the year before diagnosis and by only 15% 
shortly after diagnosis. Further, significantly lower 6MWT performance and MVIC 
in lower extremities in male and female patients were observed. 
In the intervention analyses of the 24-week exercise intervention no effects on 
physical performance were observed in intention-to-treat analyses. In the first 12 
weeks of the intervention, effects were demonstrated in knee extension in the 
exercise group. No effects were observed from week 12 to week 24. In subgroup 
analyses, with regard to patients showing good adherence, significant effects were 
observed in hip flexion from week 0 to week 24. Significant effects on physical 
performance were observed after the first 12 weeks of the exercise intervention in 
knee flexion and extension, and hip flexion. No effects were observed from week 
12 to week 24. Good adherence - including ≥75% of required exercise sessions 
and regular attendance in supervised exercise sessions - was shown in nearly 
30% (self-reported) and in 21.4% (according to the exercise log) from week 0 to 
week 24. Only few patients showed inadequate adherence. The amount of 
physical exercise sessions declined with week 10 overall. 
 Discussion 
  
Christina Titz  99 
4.2 Physical Exercise in Patients with Advanced Cancer Undergoing 
Palliative Treatment 
The literature review provided overview of physical exercise programs in patients 
with advanced cancer. Six trials were selected including 590 patients. There was a 
weak trend that resistance exercises were more applied compared to endurance 
exercises. For endpoint assessments, parameters were mainly recorded for 
physical performance, fatigue, quality of life, and pain. The results of the 
addressed studies were consistently in favor of the exercise groups. 
Previous physical exercise intervention trials have focused on cancer survivors 
who completed their treatment [20, 54, 56, 61, 76, 88] aiming on regaining 
physical functioning, increasing quality of life and reducing fatigue. This has been 
shown numerously in patients undergoing curative therapy and/or surgery. For 
advanced cancer patients undergoing palliative treatment, outcomes may be 
similar but exercise interventions have to deal with a much higher variability 
regarding patients ‘exercisability’. The analyzed RCTs showed a wide range of 
entities including many patients with gastrointestinal, lung, urological, and 
gynecological cancer representing a different approach, in comparison to studies 
done in the curative setting where mostly defined entity groups were examined 
[34, 96]. One reason for that might be that advanced cancer patients per se are 
very heterogeneous within one entity e.g. depending on the site of metastasis, 
date of first diagnose, type and progress of therapy, age, number of comorbidities 
and history of physical activity. Thus, feasibility, safety and adherence may vary 
regarding the intervention content. The reported adherence rates were ≥69% and 
no adverse events were observed. The interventions varied in content, intensity, 
type and frequency. All applied intervention programs focus on 
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resistance/strengthening exercise either supervised or home-based. Aerobic 
and/or endurance exercise training was included only in two studies [33, 74]. The 
included RCTs reported various improvements in favor of the exercising groups. 
Patients increased their physical performance [17, 33, 74, 83], decreased fatigue 
levels [33], increased physical well-being [17, 37]  and improved quality of life [33]. 
Altogether, the intervention programs were confirmed as safe and feasible for 
advanced cancer patients undergoing palliative treatment. Reasons for the 
prevalence on resistance exercise training can be seen in decreased 
musculoskeletal constitution and the risk of sarcopenia and cachexia in these 
patients [6, 94]. With regard to muscle dysfunction in cancer patients across all 
stages and diagnoses, resistance exercise has been found to be a promising 
intervention with the capacity to maintain and/or improve muscle mass, strength 
and metabolism during and after cancer treatment [20]. 
The results of the literature review have been confirmed and extended by the 
findings of two previously published literature reviews [29, 40]. Exercise has been 
indicated as a promising intervention to prevent or delay decline in aerobic fitness, 
strength, and physical function and exercise may improve QOL. However, an 
overall interpretation of outcomes was difficult as the benefits of exercise for 
patients with advanced cancer vary widely in study design, quality, implied 
exercise intervention, supervision, duration/length, and target population. 
Nevertheless, exercise appeared to be consistently beneficial [29]. On the base of 
25 studies including 1088 patients with advanced cancer - the implementation of 
exercise interventions appeared to be safe and feasible [40]. The results showed 
benefits for fatigue, quality of life, and physical performance in particular. Effects of 
physical exercise intervention studies were in favor of the experimental groups. 
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Furthermore, patients take advantage of physical exercise interventions and 
benefit physically and psychologically. 
What this study adds 
 Physical exercise interventions in patients with advanced cancer show large 
variations in frequency, time (duration), and type. 
 Patients with advanced cancer benefit both physically and mentally from 
exercise programs, including physical performance, pain, fatigue, and 
quality of life. 
 Exercise programs in patients with advanced cancer help to maintain 
independence, mobility, physical functioning, and activities of daily living. 
4.3 Physical Exercise Behavior and Performance Status in Patients with 
Advanced Lung Cancer 
The cross-sectional report of baseline data of the POSITIVE study (Part III) [109] 
compared physical performance parameter of strength and endurance capacity 
with reference data of healthy individuals [11] and calculated normative data [32]. 
Clear differences in exercise and walking behavior from shortly after to the year 
before diagnosis were demonstrated. Patients showed a strong decline in 
sports/exercise participation and low physical exercise levels shortly after first 
diagnosis. The recommended amount of 150 minutes per week was only met by 
less than a third of participants in the year before diagnosis and by only 15% 
shortly after diagnosis. Significantly lower 6MWT scores in male and female 
patients were observed. Significantly lower values were observed for MVIC in 
lower extremities. Poor muscle strength performance has been previously 
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described in patients with lung cancer [44]. In women, predominantly higher 
strength values in upper limbs compared to reference data were observed what 
might be explained by an increase in PA and exercise of nearly 20% in women in 
Germany within the last two decades [84]. The large percentage deviations of 
muscle strength in men and women in lower extremities suggest the potential of 
improvement with a physical exercise intervention program in order to counteract 
further loss of physical performance. Pilot studies have demonstrated promising 
results of an increase in muscle strength in patients with advanced lung cancer 
[59, 82]. For endurance capacity, walk distance of 6MWT was positively correlated 
with sports/exercise during youth/adolescence as well as with sports/exercise and 
walking behavior in the year before diagnosis, suggesting a potential increase in 
endurance capacity by an exercise intervention program. At baseline, patients 
showed a significantly lower walk distance of 6MWT (467±100m vs. 561m) 
compared to calculated normative data [32]. These patients, however, performed 
better compared to other data (467±100m vs. 243m) reported for advanced lung 
cancer patients [25]. The self-reported patient questionnaire indicated low levels of 
sports/exercise participation and walking in this population. Shortly after diagnosis, 
only 30% showed adequate walking behavior. Regarding the recommendations of 
the ACSM guidelines, compared to patients with advanced prostate cancer [112], 
patients showed lower PA (29% vs. 15%). These results demonstrated that 
patients practiced less sports/exercise shortly after diagnosis compared to the 
year before diagnosis. 
The limitations included that the cross-sectional design (i.e. using baseline 
assessment from a RCT) do not offer causal interferences. Assessment of 
physical performance was repeated at several time points within the POSITIVE 
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study (Part III). Longitudinal evaluations including the primary endpoint analyses 
are pending. The recruitment rate of 9.1% indicated the challenge in implementing 
a physical exercise intervention trial in this patient setting. It must be assumed that 
patients who have been previously physically active were more likely to participate 
in this study. Moreover, 76.4% were not eligible for participation resulting in a 
selected patient population. Comparisons between participants and non-
participants regarding physical exercise behavior could be of interest in future 
investigations. Physical exercise behavior of non-participants was not assessed. A 
methodological issue was that validity and reliability of the reference data of 
Bohannon et al. (1997) is questionable. Additionally worth to mention is the fact 
that PA levels have changed in the past and therefore performance reference data 
may no longer reflect current performance levels. However, no other data which 
can be applied for comparisons exist so far. 
What this study adds 
 Insights of physical exercise behavior in patients pre and post of being 
diagnosed with advanced lung cancer. 
 Patients with advanced lung cancer show reductions of physical activity and 
exercise shortly after diagnosis compared to year before diagnosis. 
 Patients show lower performance in 6-Minute walk distance and strength 
performance in lower extremities compared to healthy reference and 
normative data. 
 Sex, age, BMI <25kg/m2, sports/exercise in the youth/adolescence, and 
walking in the year before diagnosis were found to be prospective 
determinants in physical performance. 
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4.4 Effects of a 24-week Physical Exercise Program in Patients with 
Advanced Lung Cancer 
The individually tailored, combined resistance and endurance exercise program 
applied in the POSITIVE study (Part III) was based on the previously conducted 
feasibility study of an 8-week exercise intervention trial in patients with advanced 
NSCLC [59]. Endurance and resistance training are considered to be the most 
frequently performed training with lung cancer patients [1, 26, 39, 45, 49, 59, 81, 
93, 98]. The analysis of the 24-week exercise program of the POSITIVE study 
(Part III) covered evaluations from week 0 (T0) to week 24 (T2). Further analyses 
included week 0 (T0) to week 12 (T1) and from week 13 (T1) to week 24 (T2). The 
main findings showed no significant between group differences of endurance 
capacity in the intention-to-treat (ITT) analyses. Within the subgroup analysis of 
patients with good adherence and regular attendance in supervised training 
sessions, no difference in performance and/or capacity was observed. For MVIC, 
from T0 to T2 no significant between group differences were observed in the ITT 
analyses. The subgroup analysis identified significant between group differences 
in hip flexion in favor of patients with good adherence.  
Within the first 12 weeks (T0 to T1) of the intervention program, mean endurance 
capacity improved significantly in both study arms. An explanation for this 
observation could be the influence of >2nd cycle of chemotherapy application and 
temporarily regression in physical functioning and immobility. For MVIC, significant 
between group differences were observed in the ITT analyses for knee extension. 
Subgroup analyses showed significant between group differences for knee flexion, 
knee extension, and hip flexion in favor of patients with good adherence. 
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The second 12 weeks of the intervention showed improvement in 6MWT in the 
EIP-arm and decrease in the CMPC-arm in the ITT analyses. For MVIC, no 
significant between or inner group differences were found in both the ITT and 
subgroup analyses.  
Patients with advanced lung cancer experienced physical, functional and 
emotional benefits after a 6-week intervention of supervised and unsupervised, 
home-based exercise [1]. Similar results have been reported in a single-arm 
intervention trial [81]. These observations cannot be confirmed by the reported 
results. However, these findings were confirmed by results of a RCT in patients 
with advanced lung cancer [25]. No significant between group differences were 
observed in fatigue, quality of life, symptoms, physical or functional status, or 
survival. Adherence to the intervention was good and also proved once more that 
patients with advanced lung cancer are able to participate in a structured physical 
activity program. The intervention group did not increase their physical activity 
enough compared to the control group and the intervention program may not have 
been intensive enough to produce a difference in physical activity between groups 
[25].  
It must be considered that in patients with advanced cancer, additional support 
and care may play a more important role than originally assumed. The within the 
POSITIVE study (Part III) integrated CMPCs for both control and exercise arm 
provided patients a continuous, psychosocial contact for the period of 24 weeks. 
The importance of additional care applied with early integration of palliative care 
(EIPC) in patients with advanced lung cancer has been demonstrated in a 
randomized controlled trial [97]. Patients with advanced lung and GI cancer 
(n=350) of the intervention group reported greater improvement in QOL from 
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baseline to week 24. Patients did not improve significantly between baseline and 
week 12. Further, they reported that the intervention effects varied by cancer 
entity. Patients with lung cancer improved in the intervention group only. In 
patients with GI cancer, patients of the intervention and usual care group reported 
improvement by week 12. The authors suggest that EIPC may be most effective 
for patients with newly diagnosed incurable cancers, especially if targeted to the 
specific needs of each patient population [97]. 
An unexpected result was the maintenance of walk distance of 6MWT in both the 
CMPC-arm and the EIP-arm regarding ITT and also subgroup analyses. There 
was some progression both in the CMPC- and EIP-arm, however, far below 
previous reported results. Dhillon et al. 2017 found no improvement in physical 
capacity overall, however, patients doubled the walk distance of 6MWT of baseline 
performance [25]. The relevance and importance has been numerously described 
[12, 16]. The importance of an increase of the walk distance regarding MID 
(medical important difference, introduced by Granger et al. and Bohannon et al 
2003) and overall survival (as described by Jones et al. [53] and Kasymjanova et 
al. [55]) has been described previously. 
For muscle strength performance, stagnation was observed with sometimes a 
slight progression in mainly the EIP-arm. The results overall showed no decrease 
of strength capacity over the intervention period of 24 weeks. In upper limbs, there 
was no change in progression between the two groups. In lower limbs, the 
observed progressions were in favor of the EIP-arm. Significant between group 
differences from T0 to T1 were observed in knee extension. The results of the 
MVIC reflect the results of previous results of physical exercise intervention 
programs in patients with advanced cancer, also demonstrated in literature 
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reviews on exercise in patients with advanced cancer. In patients with lung cancer, 
however, pilot trials have proven not only safety and feasibility but also beneficial 
effects on resistance capacity. The pilot trial of the POSITIVE study (Part I) 
covered eight weeks instead of 24 weeks. Within in the POSITIVE study (Part III), 
less supervised exercise sessions within the inpatient setting due to a change in 
treatment regimen were provided. The within Part II of the POSITIVE study [59] 
continuously, three times weekly provided exercise input may have contributed to 
an extraordinary increase in physical performance. With regard to the results 
shown in the cross sectional baseline data analysis, physical performance and 
exercise attendance was low and even decreased more with diagnosis. A 
performance decline was prevented by the intervention program, even if both 
groups have taken benefit from it. (Partly) home-based exercise program was 
proven safe and feasible in cancer patients and it was proven safe and feasible for 
patients with advanced lung cancer [59]. In this study, patients were required to 
exercise at least three times per week, 1x in the training facility and 2x at home 
with use of the exercise manual. With no option to control the exercise session or 
the individual intensity, in patients with no exercise experience a home-based 
exercise program may not be very essential. 
Before each training session, patients were asked to self-assess pain, fatigue, 
emotional status, and distress to choose the appropriate exercise volume 
category. Patients were instructed to rate the individual intensity of the exercise 
sessions according to the Borg Scale (12-14 for endurance exercise, 14-16 for 
resistance exercise). However, the results showed almost none significant 
between group differences in upper and lower limbs. Thus, the applied training 
intensity may not be efficient enough or high enough. It must be considered that a 
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home-based exercise program may not provide the required intensity. Another 
research group has also failed to proof clear benefit of physical exercise programs 
in patients with advanced lung cancer [25]. Results of a similar trial - the previously 
introduced EXHALE-study [80] - are pending. 
Patients of this population showed a relatively low level of education and most 
patients were smokers or former smokers. This may contribute to a generally 
reduced understanding of a healthy lifestyle. In many cases, patients did not get 
support from their family members to be involved in a physical exercise study. 
Educational aspects should be considered in future studies to advise patients and 
relatives on the beneficial effects of exercise and physical activity. 
Generally, patients of the EIP-arm provided feedback including good acceptability 
of the exercise program and improvement in self-efficacy. Unfortunately, this was 
not covered in the physical performance assessments. Thus, the question remains 
to what extend patients establish a connection between the exercise program and 
the self-reported improvement in physical well-being, quality of life and self-
efficacy. 
It must be assumed that predominantly side effects - either therapy-related or 
caused by the disease itself - lead to reductions of the adherence to the 
intervention program. Adequate and good adherence was provided in less than 
50% of patients of the EIP-arm. Patients with brain radiation were not able to get 
to the training facilities as they were not allowed to drive. Others did not feel well 
enough to exercise with other patients or healthy patients. This indicates the 
support for an individualized and very adapted exercise program to take patients’ 
concerns into account. Supervised exercise sessions worked out very well both at 
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the clinic as well as in training facilities in or near the patients’ hometown. Even 
patients who had no experience in exercising and/or training facilities showed 
good adherence. Some patients did not show the required understanding in being 
able to do something or themselves by exercising and were therefore barely 
motivated. 
In treatment-related analyses, percentage change of walk distance, knee 
extension, and elbow flexion was shown. From T0 to T1, performance of 6MWT of 
patients with RT only improved most - the CMPC-arm even higher compared to 
the EIP-arm. In knee extension and elbow flexion, patients of the EIP-arm with RT 
only improved while patients of the CMPC-arm declined in performance. The 
lowest percentage change was observed for patients with chemotherapy only. 
From T0 to T2, the percentage change of performance of walk distance of 6MWT 
showed overall higher increase in the CMPC-arm compared to the EIP-arm. In 
knee extension and elbow flexion, the EP-arm improved performance with higher 
values of percentage change. With regard to treatment-related evaluations, 
completion rates of chemotherapy will play an important role in pending analyses. 
In previous studies, it has been observed that patients with better physical 
capacity showed lower complication rates and higher completion rates of 
chemotherapy [23, 68, 105, 106].  
Sarcopenia and loss of muscle mass in patients induced by anticancer treatment 
will constitute an essential discussable point in the future [7, 15, 73, 95]. Beyond 
this, the rising application of immunotherapy supplements in lung cancer may 
change treatment regimen completely and offers new insights in treatment-related 
side-effect management. 
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Strengths of the POSITIVE study (Part III) include the high standard of reliability 
and validity of a randomized controlled trial with application of standardized 
questionnaires and assessment tools for physical performance. The study 
population offered a homogenous population of non-operable patients with lung 
cancer undergoing palliative treatment.  
Limitations of the study must be considered in a possible contamination of the 
control arm as physical activity (e.g. brief walks) were performed in most patients 
throughout the intervention and exercise behavior was assessed only once at 
study enrolment. However, according to the weekly phone calls practiced by the 
advanced practice nurse, an exercise program including structured resistance and 
endurance exercise was only performed on very few patients of the control arm. 
The assessor of physical performance testing procedures was not blinded what 
may be considered as a bias factor. Further, the weekly phone calls included often 
more than just a simply record of side-effects and symptom according to the 
ESAS. Moreover, many patients, regardless of the study arm, found help, support, 
and encouragement in the weekly provided contact what may also result in a bias 
factor against other study populations. 
What this study adds 
 Patients with good adherence and regular supervised exercise sessions 
showed significantly better performance in knee extension after 12 weeks. 
 Treatment-related progress of physical performance was observed in 
endurance and resistance parameters.  
 Uptake and amount of physical exercise sessions decrease in the course 
treatment. 
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 Previously reported benefits of physical exercise intervention programs 
cannot be confirmed in this patient setting. 
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4.5 Conclusion 
With increasing evidence in other cancer entities that support beneficial effects of 
physical exercise on fatigue, quality of life and physical performance, studies 
investigating the effects of physical exercise in patients with advanced lung cancer 
remained rare. The third part of the POSITIVE study - in extension of the 
POSITIVE study (Part I) and (Part II) - adds to current knowledge on feasibility and 
safety but moreover on impact on various outcome parameters in patients with 
inoperable lung cancer. The results presented within this work do not consistently 
support the hypothesis that an exercise intervention program beneficially effects 
physical performance in these patients. It has to be considered that in these 
patients, psychosocial support may play a more important role that also affects 
quality of life and physical well-being. Therefore, psychosocial support was 
provided to all study patients. 
For the future, a valuable finding of the baseline analyses revealed an alarmingly 
reduction of physical activity and exercise behavior shortly after diagnosis. This 
supports an early integration of physical exercise during anti-cancer treatment. 
The impact of a physical exercise intervention program should induce on 
accompanying and helping patients to maintain independent functions as long as 
possible. To provide more support by relatives and family members, it may be 
necessary to integrated these in exercise sessions to additionally provide social 
support and physical contact. With the effects observed in patients with good 
adherence and regular attendance in supervised training sessions, the exercise 
intervention program resulted in measureable benefits and should therefore be 
implemented in the clinical setting. 
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In the POSITIVE study (Part III) further analyses are yet in progress as well as 
under preparation. The results of the primary endpoints after 12 weeks of the 
intervention (quality of life, physical well-being, and physical fatigue) are pending 
as well as analyses of immunological parameters. Beyond this, evaluations of CT 
scans with regard to cachexia and sarcopenia are yet in preparation as well as 
overall survival analyses. The clinical parameters will offer new insights in 
beneficial effects on immune functions caused by physical exercise. Furthermore, 
analyses will include overall survival with regard to quantitative evaluations of body 
composition recorded on computer tomography scans and individual response to 
the exercise program in blood markers. 
Future studies in patients with lung cancer should consider psychosocial support 
in addition to a physical exercise intervention program. Furthermore, amount and 
intensity of the exercise sessions should be individually tailored to a patient’s 
condition and shape. Supervised exercise sessions should be integrated to ensure 
efficient intensity and appropriate extent of the respective training session. 
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5. Summary 
Patients with advanced lung cancer suffer of incurable disease with limited 
prognosis and experience multidimensional impairments during their course of 
disease. In the field of exercise oncology, increasing evidence previously 
supported the implementation of exercise programs in various cancer entities. The 
evidence includes mainly patients with early stage cancer and/or cancer survivors. 
However, there is also growing evidence that physical exercise is safe and 
feasible for advanced cancer patients but knowledge is limited. Also as a part of 
this thesis, a comprehensive literature search was carried out to provide an 
overview of randomized controlled physical exercise programs implemented in 
patients with advanced cancer undergoing palliative treatment. Six studies 
provided data of 590 cancer patients with advanced disease. Beneficial effects of 
the exercise interventions were reported for both physical and psychological 
outcomes. General exercise recommendation for patients undergoing palliative 
treatment cannot be derived from the analyzed studies due to the large 
heterogeneity of the applied exercise programs. 
As one of the largest RCTs worldwide in patients with advanced lung cancer, the 
POSITIVE study (Part III) was implemented to add to current knowledge. The 
cross-sectional baseline analyses revealed reduced physical performance, 
especially in strength capacity in lower extremities and endurance. However, these 
results showed promising potential for a structured combined, individually tailored 
resistance and endurance exercise program in this patient population. The 
observed decrease in physical activity and exercise shortly after diagnosis 
supports the importance of an early implementation of exercise interventions in 
oncology. 
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The intervention program was conducted for 24 weeks in which all study patients, 
regardless of the study arm, were contacted once weekly by the study personnel. 
The results showed significant differences in strength performance after 12 weeks, 
especially with regard to subgroup analyses. Within the second 12 weeks and 
overall the 24 weeks no significant effects were observed. Patients’ adherence to 
the exercise program differed from the first to the second 12 weeks of the 
intervention due to treatment and/or disease related side-effects resulting in 
decreasing condition. 
It remains unclear why no beneficial effects on physical performance of the 
individually tailored exercise program have been observed in this patient 
population. It must be considered that the intensity of the exercise program was 
not efficient enough. Other reasons may be considered with regard to insufficient 
adherence to the exercise program in order to a lack of motivation and/or therapy-
related side-effects. Nevertheless, patients’ feedbacks support the importance of a 
complementary supplement to treatment including the exercise program and the 
continuous contact.  
Based on the observed subgroup analyses including patients with good 
adherence, physical exercise should be implemented early in patients undergoing 
palliative treatment to support patients to maintain independent functions as long 
as possible. 
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